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discoveries, is not 'Eureka!' but 'That's funny...'” 
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RESUMO 
 
A complexidade do nosso sistema nervoso permite-nos apreciar momentos de reflexão, 
arte e imaginação, veiculada ou não pela linguagem. A unidade funcional que o permite é 
o neurónio, que dispara potenciais de acção seguidos de potenciais sinápticos que no 
conjunto são considerados a unidade básica de informação. O potencial de acção é um 
ponto central da regulação do sistema nervoso, que reflete não só a função de canais 
iónicos e outras estruturas que, ao nível subcelular, o modulam, mas também constitui a 
base da comunicação entre estruturas cerebrais e determina a coerência ou não de 
actividade neuronal. Os vários níveis de regulação do potencial de acção e do potencial 
sináptico interagem entre si e garantem o correcto controlo da excitabilidade. Contudo, 
dada essa flexível interacção, um pequeno desequilíbrio num dos níveis manifesta-se no 
sistema inteiro, como é o caso da epilepsia: uma mutação num canal de sódio dependente 
de voltagem, por exemplo, é suficiente para tornar o indivíduo susceptível a convulsões. 
Estas caracterizam-se por um desequilíbrio entre o tónus excitatório/inibitório que conduz 
a actividade neuronal anormal, excessiva e hipersíncrona no cérebro, tornando o indivíduo 
incapaz de conscientemente controlar o seu corpo por breves momentos, o que resulta 
frequentemente em fatalidades. 
Actualmente, 30% dos pacientes com epilepsia não respondem aos antiepilépticos 
actuais, ou seja, é fármaco-resistente, o que acarreta 75% do fardo socioeconómico 
associado a esta doença neurológica. Os mecanismos que estão na base da resistência 
aos fármacos são partilhados por outras patologias e não estão necessariamente 
relacionados com os mecanismos de epileptogénese per se. Para ultrapassar esta 
barreira, uma estratégia a seguir consiste em estudar os mecanismos endógenos 
anticonvulsivantes do cérebro e potenciá-los, como é o caso da adenosina.  
A adenosina é uma molécula ubíqua em todas as células do corpo humano, envolvida 
em processos básicos de suporte celular (como suporte estrutural nos ácidos nucleicos e 
suporte funcional na transferência de energia através de ATP). No sistema nervoso, é um 
importante neuromodulador que apresenta propriedades anticonvulsivantes, 
principalmente mediadas, mas não restringidas, ao receptor A1R da adenosina. Estes 
receptores são os mais abundantes, sendo expressos numa grande variedade de tecidos 
e órgãos, incluindo o sistema nervoso e o sistema cardiovascular. A activação dos 
receptores A1 tem um efeito anticonvulsivante ao diminuir a transmissão sináptica 
excitatória, diminuindo, assim, a probabilidade de actividade neuronal síncrona e 
excessiva. Os efeitos da activação dos receptores A1 manifestam-se pré- e pós 
sinapticamente. Pré-sinapticamente, a activação dos receptores A1 acoplados à proteína 
Gi/o resulta na diminuição de cálcio, necessário na libertação de vesículas de 
neurotransmissor. Assim, observa-se uma libertação de neurotransmissor assíncrona, 
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responsável por um potencial excitatório pós-sináptico (EPSP) de menor amplitude. Pós-
sinapticamente, a activação dos receptores A1 resulta na activação de canais de potássio, 
conduzindo à hiperpolarização do potencial de membrana. A redução da transmissão 
sináptica através dos receptores A1 deve-se, assim, à menor amplitude do potencial 
excitatório pós-sináptico, hiperpolarização do potencial de membrana e resistência da 
membrana diminuindo de modo global a transmissão sináptica. 
A utilização de adenosina em modelos de epilepsia fármaco-resistente foi capaz de 
prevenir convulsões. Contudo, a presença dos receptores A1 no sistema periférico, 
nomeadamente no sistema cardiovascular, tornam a administração sistémica da 
adenosina impraticável, dados os severos efeitos secundários resultantes da depressão 
da actividade cardíaca. Uma alternativa seria o desenvolvimento de análogos da 
adenosina que fossem selectivos e de elevada afinidade para os receptores A1R do 
sistema nervoso central e não para o sistema periférico.  
O fármaco MRS5474, desenvolvido pelo grupo de investigação do Prof. Keneth 
Jacobson, apresenta tais características, com um efeito anticonvulsivante num modelo de 
epilepsia fármaco-resistente (6Hz) quando administrado intraperitonealmente em ratinhos 
sem os típicos efeitos secundários periféricos observados por um agonista clássico 
selectivo dos receptores A1, CCPA. 
O mecanismo de acção do MRS5474 é ainda desconhecido, mas o seu efeito in vivo 
parece apontar para selectividade para o sistema nervoso em vez do sistema periférico. 
Tal pode ocorrer se o MRS5474 actuar apenas sobre um alvo sináptico que apenas se 
encontra presente no sistema nervoso central. 
Compreender o alvo sináptico e o mecanismo de acção do MRS5474 pode permitir a 
identificação de um novo alvo para o desenvolvimento de novos fármacos antiepilépticos. 
Neste trabalho, a hipótese testada foi a de que o MRS5474 diminui a transmissão sináptica 
excitatória nas células piramidais CA1 do hipocampo através de activação dos receptores 
A1. Esta estrutura é a mais implicada na epilepsia de lobo temporal, o tipo mais comum de 
epilepsia fármaco-resistente. 
De modo a estudar a transmissão sináptica excitatória nas células piramidais CA1, 
utilizaram-se fatias agudas de hipocampo de ratos wistar wild-type (3-8 semanas). As 
fibras que estimulam as células piramidais CA1 (Colaterais de Schaffer ou Via Perforante) 
foram electricamente estimuladas e as correntes pós-sinápticas excitatórias (EPSC) 
geradas em células piramidais CA1 registadas pela técnica de patch-clamp, no modo 
whole cell. Para se isolar a componente excitatória da transmissão sináptica, bloqueou-se 
farmacologicamente os receptores ionotrópicos GABAA responsáveis pela componente 
inibitória rápida, adicionando ao meio de perfusão Picrotoxina (50 µM). Após se obter 
estabilidade no registo da amplitude de EPSP (durante pelo menos 10 minutos) os 
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fármacos a testar foram adicionados ao meio de perfusão, CCPA (30 nM) ou MRS5474 
(120 nM), a concentrações aproximadamente equipotentes para os receptores A1. 
Em primeiro lugar, foi importante testar a activação dos receptores A1 com um agonista 
clássico selectivo (CCPA 30 nM), cujos efeitos estão amplamente descritos na literatura 
para obter um controlo experimental e metodológico. Observaram-se os efeitos esperados 
da activação dos receptores A1R: diminuição da amplitude das correntes pós-sinápticas 
excitatórias em 70 ± 5,2 % (n=4, p<0.001), diminuição da resistência membranar em 
9,9±1,3% (n=4, p<0.05) e hiperpolarização do potencial de membrana estimado em 
6,3±0,55 mV (n=3, p<001) a partir da medição de corrente injectada para manter o 
potencial de membrana constante a -70 mV.  
Relativamente ao MRS5474, este não alterou significativamente a amplitude dos 
EPSPs (128 ± 12,3%, n=8, p>0.05), embora se tenha observado uma elevada tendência 
para disparo de potencial de acção, contaminando os EPSPs e destabilizando o registo. 
De modo a isolar-se os EPSPs dos potenciais de acção, utilizou-se um bloqueador de 
canais de sódio dependentes da voltagem, QX-314 (5 mM), o que reduziu a variabilidade 
do efeito do MRS5474 sobre os EPSPs mas não o alterou significativamente (100 ± 2,40%, 
n=5, p>0.05). Dada a tendência que as células piramidais CA1 apresentaram para disparar 
potenciais de acção na presença de MRS5474, o seu efeito na excitabilidade intrínseca 
foi testado através do registo de padrões de disparo. A mesma fatia foi usada para medir 
padrões de disparo de células piramidais CA1 antes e depois da exposição (>1 hora) ao 
MRS5474. De facto, a presença de MRS5474 (120 nM) aumentou excitabilidade nas 
células piramidais CA1, através de despolarização da membrana (6,1±1,5 mV, n=4 
Control, n=8 MRS5474, p<0.01), aumento da frequência de disparo de potenciais de acção 
(157 ±11,8%, n=4 Control, n=8 MRS5474, p<0.01) e diminuição da amplitude das 
correntes rápida (fast) e média (médium) de hiperpolarização da fase de repolarização do 
potencial de acção (‘Afterhyperpolarization’ - AHP) fAHP (42±8,7%, n=4 Control, n=8 
MRS5474, p<0.01) e mAHP (28±5,7%, n=4 Control, n=8 MRS5474, p<0.001) a frequência 
máxima. 
Pode concluir-se que o MRS5474 (120 nM) facilita a excitabilidade das células 
piramidais CA1 no hipocampo, sem alterar as correntes sinápticas excitatórias, o que por 
si só não explica a sua acção anticonvulsivante in vivo. Pelo contrário, sugere um papel 
pro-excitatório do fármaco. Contudo, é necessário ter em conta que os resultados obtidos 
corresponderam às correntes excitatórias de células piramidais CA1 no hipocampo de 
ratos sem patologia. O efeito de MRS5474 (120 nM) na componente inibitória da 
transmissão sináptica das células piramidais CA1 assim como o seu efeito em 
interneurónios, células inibitórias, não foi ainda estudado. Contudo, é fundamental para se 
poder concluir acerca do mecanismo de acção do MRS5474 como anticonvulsivante, quer 
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em condições depolarizantes (comuns durante convulsões) quer na excitabilidade de 
interneurónios.  
 
Palavras-chave: Epilepsia Farmacoresistente, Adenosina, Receptores A1 para 
adenosina, MRS5474, CCPA  
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ABSTRACT 
 
Activation of adenosinergic system in epileptogenic conditions is an efficient 
endogenous anticonvulsivant mechanism that protects against pharmacoresistant 
epilepsy. However its systemic administration also triggers unacceptable side effects, 
mainly cardiovascular, that prevent its use as an antiepileptic drug (AED). 
A new adenosine derivative MRS5474 was shown to protect against elicited seizures 
in vivo in a pharmacoresistant epilepsy model without significant side effects, unlike the 
classical selective A1R agonist CCPA. 
In this work, we aimed at determining the synaptic target of MRS5474 which may help 
shift the search for new AED towards a novel target. According to binding and adenylate 
cyclase activity studies, MRS5474 has high A1R affinity and full agonism with moderate 
selectivity against other adenosine receptors (e.g. A3R). We thus hypothesized that 
MRS5474 decreases excitatory synaptic transmission in CA1 pyramidal cells of the rat 
hippocampus through A1R activation. 
Acute hippocampal slices from wild-type Wistar rats (3–8 weeks) were used to record 
excitatory postsynaptic currents (EPSCs) and action potentials (AP) (whole-cell patch 
clamp) from pyramidal neurons of the CA1 area. Upon electrical stimulation of Schaffer 
Collaterals, EPSCs were recorded from pyramidal cells under voltage clamp at a Vh of -
70 mV. To study MRS5474 (120 nM) effect on excitability properties of the studied cells, 
action potentials were measured under current clamp after at least 1h exposition to 
MRS5474. The effect of MRS5474 (120 nM) was compared with that of a standard A1R 
agonist, CCPA (30 nM), at an equipotent concentration for the A1R.  
The results show that CCPA (30 nM) had a typical A1R activation effects: inhibition of 
excitatory synaptic transmission by decreased EPSC amplitude and membrane potential 
hyperpolarization, both effects being prevented in the presence of an A1R antagonist 
(DPCPX, 100 nM). Unlike CCPA, MRS5474 (120 nM) did not behave as a classical A1R 
agonist, since it had no inhibitory effect on excitatory synaptic transmission and even 
presented a pro-excitatory effect on CA1 pyramidal cell intrinsic excitability properties: 
resting membrane potential depolarization, increased firing frequency and altered 
afterhyperpolarization (AHP) current components (decreased fast and medium AHP and 
increased slow AHP). 
So far, a pro-excitatory role of MRS5474 on excitatory synaptic transmission on CA1 
pyramidal cells of healthy rat hippocampus is not able to explain the MRS5474 
anticonvulsivant properties in vivo in a model of pharmacoresistant epilepsy (6 Hz). If the 
increased intrinsic excitability caused by MRS5474 on CA1 pyramidal cells is also 
observed at a slight greater extent in interneurons, then the global net effect of MRS5474 
would be inhibitory. This hypothesis could explain not only its anticonvulsivant properties 
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but also the lack of observable side effects. Further studies evaluating the influence of 
this drug under more depolarizing conditions (often occurring during seizures) and in the 
excitability of inhibitory neurons are required to understand the antiepileptic mechanism 
operated by this drug. Being able to bypass the negative implications of using the 
adenosinergic system and take advantage of its powerful anticonvulsivant properties is a 
promising track to fight pharmacoresistant epilepsy.  
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1. INTRODUCTION 
In 400 BC, Hippocrates stated that “(…) All the (…) most difficult [diseases] to be 
understood by the inexperienced, fall upon the brain.” (Hippocrates, in On the Sacred 
Disease, 400 BC). In 2016, the complexity of our brains continues to inspire 
neuroscientists to work on a still unresolved question:   
“How can a three-pound mass of jelly that you can hold in your palm imagine 
angels, contemplate the meaning of infinity, and even question its own place 
in the cosmos? (Ramachandran, 2010).  
Even though we are still unable to answer such complex questions, the basic 
principles of brain functioning have been unravel. Understanding this basic principles 
will be necessary to grasp the aim of this work: unraveling the mechanism of action of 
a new putative antiepileptic drug.  
 
 
 
1.1. Neuronal Communication 
Using the improved Golgi silver impregnation method, Santiago Ramón y Cajal 
identified neurons as the functional unit of the nervous system (Ramón y Cajal, 1911). 
Being individualized units, neuronal communication relies upon signals of different 
nature, electrical and chemical, so that the information can be carried out within the 
neuron and between neurons, respectively.   
Within the neuron, the information is generated and propagated by an electrical 
signal known as the action potential (Gasser and Erlanger, 1922). This flow of 
information is communicated to the next neuron, which is usually in close but not 
physical contact, through a synapse (Sherrington, 1897). In this structure, the electrical 
signal is converted to a chemical signal that induces a synaptic potential, traveling along 
the dendrites to the soma of the post-synaptic neuron. If sufficient, it will trigger the 
generation of an all-or-none action potential (Adrian, 1914) in the post-synaptic neuron 
and the information can be carried out in an extremely fast fashion, in the order of 
miliseconds (ms). 
From this simple and brief explanation of neuronal communication, two concepts 
gain special relevance: the action potential and the synaptic transmission.  
 
1.1.1. The action potential 
The action potential is believed to be a basic information unit used by the brain. 
The electrical excitability that allows a neuron to fire an action potential is based on the 
presence of proteins embedded in the cellular membrane that are electrically active 
(Figure 1.). These include two main groups: 1. ion channels that allow electrically 
charged ions to flow across the membrane and 2. ion pumps that actively transport ions 
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across the membrane. Ion channels can be divided into three main categories: A. 
voltage-insensitive, B. voltage–gated or C.  ligand-gated. This distinction is based upon 
its mechanism of action: voltage-insensitive channels (A) are always open while gated 
channels open upon a signal, being it  a difference in membrane voltage (B) or the 
presence of a molecule (C) which leads to a conformational change, allowing ions to 
cross the membrane. Ion pumps are responsible for maintaining a negative potential 
between the intra and extracellular space, the resting membrane potential (RMP), 
which is primarily generated by voltage-insensitive channels permeable mainly to K+.  
When the membrane, typically at -70 mV, depolarizes gradually due to chemically-
activated ion channels to a specific membrane potential, called AP threshold, voltage-
gated ion channels are activated and these are the basis for action potential generation. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Biomolecular basis for the electrical excitability of neurons. 
The resting membrane potential results from an electrochemical gradient maintained by the 
Na+/K+ pump, at energy cost (ATP breakdown), and voltage-insensitive ion channels, mainly 
K+ channels. This electrochemical gradient is fundamental as a power source that allows 
the generation of action and synaptic potentials. This is accomplished by transient 
electrochemical gradient collapse achieved when ion channels open, upon ligand or voltage 
sensing, or both. Legend: NT: neurotransmitter.  
 
1.1.2. Phases of the action potential 
Hodgkin and Huxley were the first to describe the mechanism of action potential 
propagation and how several families of voltage-gated ion channels are the basis for 
the different phases of the action potential, such as sodium, potassium and calcium 
channels (Hodgkin and Huxely, 1952a-e). 
Before briefly analyzing the phases of the action potential, it is fundamental to 
understand the types of potentials neurons generate.  A “potential” results from a 
difference in electrical charges; neurons exhibit three types of potentials – resting 
membrane potential, synaptic potential and action potential. The resting membrane 
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potential (RMP) results from the difference in the electrical changes across the 
membrane, the intracellular compartment being negative (around -70 mV) and implies 
a constant energy effort of ion pumps. The synaptic potential occurs at synapses, where 
the released neurotransmitters from the pre-synaptic neuron bind to ligand-activated 
ion channels, inducing a local synaptic potential that travels along the dendrite to the 
post-synaptic neuron soma. This synaptic potential may be excitatory (if it causes 
membrane potential depolarization) or inhibitory (causes membrane potential 
hyperpolarization). These potentials are designated by Excitatory Post-Synaptic 
Potential (EPSP) or Inhibitory Post-Synaptic Potential (IPSP), respectively. If the 
summation of synaptic potentials depolarizes the membrane potential to its threshold 
value, an action potential is triggered and the information is carried from one neuron to 
the next. 
The action potential is a transient event in which the membrane potential rapidly rises 
and falls, in a scale of miliseconds (ms), typically described as in Figure 2. The phases 
of the neuronal action potential are indicated along with the channels involved in each 
step. Three main phases can be distinguished: 1. Depolarization, 2. Repolarization and 
3. Afterhyperpolarization (AHP). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Neuronal action potential. Phases of action potential are indicated along with the 
channels involved in each step. Three main phases can be distinguished: 1. Depolarization, 2. 
Repolarization and 3. Afterhyperpolarization, subdivided in fast Afterhyperpolarization (fAHP), 
medium Afterhyperpolarization (mAHP) and slow Afterhyperpolarization (sAHP). Voltage-gated 
sodium channels are mainly responsible for the depolarization while potassium channels are 
mainly responsible for the Repolarization and Afterhyperpolarization. Potassium channels are 
comprised of three main families: KV – voltage-gated K+ channels, KCa – Ca2+-activated K+ 
channels and Kir – Inward Rectifier K+ channels. Calcium conductance property distinguishes 
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KCa channels in BK (Big Ca2+ conductance), SK (Small Ca2+ conductance) and IK (Intermediate 
Ca2+ conductance). (Based on Goodman, 2008). 
 
1. Depolarization:  
Upon sufficient membrane depolarization, closed voltage-gated Na+ channels open, 
increasing permeability to Na+, and sodium ions flow inward toward its 
electrochemical equilibrium  potential (ENa ~ +55 mV). This causes the 
depolarization or rising phase of the action potential. Voltage-gated Na+ channels 
are both fast activating and fast inactivating, thus close quickly (at about + 30 mV), 
before ENa is reached. 
 
2. Repolarization: 
Voltage-gated K+ channels, which take slightly longer than voltage-gated Na+ 
channels, begin to open and allow K+ to move out of the cell, toward its 
electrochemical equilibrium potential (EK ~ - 90 mV). This causes the repolarization 
or falling phase of the action potential and reestablishes the resting membrane 
potential. 
 
3. Afterhyperpolarization: 
Voltage-gated K+ channels and other K+ channels remain open and the membrane 
potential undershoots the resting membrane potential, approaching the 
electrochemical equilibrium potential for K+ (EK ~ - 90 mV). This phase is called 
Afterhyperpolarization (AHP) or refractory period. It is constituted of 4 phases that 
can be described upon their temporal dynamics and underlying currents (Table 1): 
3.1. fast AHP (fAHP) 
Lasting 1 to 2 ms, the fAHP follows single action potentials and is carried by 
1.Voltage-gated K+ channels, opened during the repolarizing phase that remain 
open, and 2. calcium and voltage-gated BK channels (Storm 1987, Sah and 
Faber, 2002).  These channels belong to a family of calcium-activated potassium 
channels that may be distinguished based on their potassium conductance:   
- BK (Big K+ conductance channels) 
- IK (Intermediate K+ conductance channels) 
- SK (Small K+ conductance channels) 
BK channels are activated by voltage changes and micromolar Ca2+ 
concentrations (due to N-type Ca2+ channels). Co-localization of N-type Ca2+ 
channels and BK channels was observed in many neuron types, including CA1 
pyramidal cells (Marrion and Tavalin, 1998). Calcium sensing by BK channels is 
direct, due to the presence of a cytoplasmic C-terminal domain (CTD) (Wu et al. 
2010). 
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3.2. After-DePolarization (ADP) 
Lasting 3-4 ms, the ADP follows single action potentials and is mediated, in part, 
by a Ca2+ tail current mediated by R-type Ca2+ channels (Metz et al., 2005) and 
may also have a contribution from persistent Na+ current (Yue et al., 2005). 
3.3 slow post-burst AHP  
This component may be divided into two components: the medium AHP 
(mAHP) and slow AHP (sAHP). After a single action potential, it is only possible 
to measure mAHP, whereas after a train of action potentials it is possible to 
identify mAHP and sAHP, which lasts more than hundreds of ms up to seconds.  
3.3.1. medium AHP (mAHP) 
Lasting 20 - 100 ms, the mAHP is carried by apamin-sensitive SK (Small-K+ 
conductance) (Sah and Faber, 2002). SK channels are insensitive to voltage 
and are activated by submicromolar Ca2+ concentrations (due to L-type Ca2+ 
channels). Similarly to BK channels, SK channels co-localize, at the pre-
synaptic terminal, with L-type Ca2+ channels (Marrion and Tavalin, 1998; 
Bowden et al., 2001), through which Ca2+ influx is directly sensed by a 
calmodulin domain in SK channels (Adelman, 2016). Both of these calcium-
activated potassium channels (KCa channels), SK and BK channels, highlight 
the importance of submembrane calcium microdomains: Ca2+ can reach 
concentrations up to 200 to 300 micromolar and this information can be 
specifically sensed by determined channels without affecting other calcium 
signaling pathways (Rizzuto and Pozzan, 2006). 
3.3.2. slow AHP (sAHP)  
The sAHP develops after the firing of a train of action potentials with a time 
course of hundreds of milliseconds and decays with a time course of seconds. 
It was first described more than 30 years ago (Hotson and Prince, 1980; Alger 
and Nicoll, 1980; Schwartzkroin and Stafstrom, 1980) but the underlying 
channels have only recently been uncovered. Ca2+-activated K+ channels have 
long been thought to be in the basis of sAHP (Hotson and Prince, 1980; Alger 
and Nicoll, 1980; Schwartzkroin and Stafstrom, 1980; Brown and Griffith, 
1983; Madison and Nicoll, 1984; Lancaster and Adams, 1986; Schwindt et al., 
1992).  
The potassium channels underlying sAHP have been recently identified: 1. 
KCNQ, 2. IK channels, 3. KATP and 4.Kir.  
Unlike fAHP and mAHP, the sAHP depends on diffusible cytosolic calcium 
sensors (like Hippocalcin and neurocalcin δ (Tzingounis et al., 2007) that sense 
the intracellular Ca2+. Hippocalcin, for example, upon binding to intracellular 
Ca2+, exposes a myristoylated group and translates to the plasma membrane, 
to activate the sAHP potassium channels in the plasma membrane. 
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Table 1. Summarized properties of AfterHyperPolarization components of Action Potential 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The fact that sAHP is activated by cytosolic calcium sensors is consistent 
with early findings that the sAHP seems to be sensing the bulk calcium in the 
cytosol and not the calcium inflow in microdomains, as is the case for the fAHP 
and mAHP. It also reconciles the fact that sAHP current occurs with a 150 ms 
delay of Ca2+ channels activation when no calcium ions are available no more.  
This is now explained by this transduction system of a calcium sensors. The K+ 
channels that are activated through this process are the 1. KCNQ channel family 
members (potassium channels, voltage-gated, KQT-like family). They were 
shown to contribute to sAHP in CA1 and CA3 pyramidal cells (Tzingounis et al., 
2008 and 2010) and, later, a specific blocker of sAHP, UCL2077, was shown to 
block KCNQ channels (Soh and Tzingounis, 2010), further strengthening the 
idea that KCNQ underlie sAHP. However, even though blockage of Hippocalcin 
or blockage of KCNQ had significantly reduced the sAHP (by over 50% in CA3 
pyramidal cells), other channels need to contribute to sAHP since knockout of 
specific members of the KCNQ family did not completely abolish the sAHP. 
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Also, even though Hippocalcin is highly expressed in hippocampal neurons, it 
is not highly expressed in all parts of the brain that exhibit a sAHP (Villalobos 
and Andrade, 2010).  
Other Ca2+-dependent channels were shown to underlie the sAHP in CA1 
pyramidal cells. Belonging to the Ca2+-dependent K channels (SK, BK), 2. IK 
channels (also named SK4, IKCa, KCa3.1.) underlie the sAHP, reducing 
temporal summation of EPSPs and mediating spike accommodation (King et 
al., 2015). Similarly to SK and BK channels, calcium is sensed by IK channels 
through a direct mechanism: a calmodulin domain in C-terminal. 
Pharmacological blockade or genetic knockout of these channels completely 
abolish the first 5-30 ms of sAHP amplitude, increased AP frequency and 
decreased spike accommodation of a train of APs. This highlights its importance 
in sAHP in CA1 hippocampal neurons.  
However, these channels were only recently found in specific neurons 
(Wulff et al., 2007: not detected in the CNS; Engbers et al., 2012: detected in 
cerebellar Purkinje neurons; Turner et al., 2015: detected in rat or mouse 
neocortex, hippocampus, thalamus, and cerebellum with differential pattern of 
distribution between cells). This heterogeneous distributions suggests that there 
are several channels contributing to the sAHP, maybe even different channels 
in different cell types. KATP channels, for example, have been suggested to 
contribute to sAHP in granule cells in the mouse dentate gyrus, since a KATP 
blocker, glibenclamide, reduces the amplitude of sAHP in these cells (Tanner et 
al., 2011). 
Common to all neurons, inwardly rectifier K+ channels (Kir channels) (Isomoto 
et al. 1997) are activated by hyperpolarization, leading to inward fluxes of K+ 
that depolarize the axon and bring the membrane potential back toward the 
resting membrane potential. Kir channels open after  ~30 ms following an action 
potential and reach steady state over 100-200 ms. Thus, they are involved in 
the last phase of recovery toward resting membrane potential following an 
action potential or a train of action potentials.  
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1.1.3. Functional interpretation of action potential and its components in 
health and disease 
The action potential (AP) components, especially the AfterHyperpolarization (AHP), 
have an important function role at a network level. This results from the central role that 
the action potential(s) assumes in neuronal communication, connecting all levels of 
organization.  
We may describe the multiple levels of networks in the nervous system in a simplified 
way consisting in: 
- nanocircuits – computation within a neuron, resulting from the underlying 
biochemical machinery that mediates key neuronal properties; 
- microcircuits - few interconnected neurons may form a microcircuit and perform 
sophisticated tasks such as mediate reflexes, process sensory input and generate 
locomotion; 
- macrocircuits - multiple embedded microcircuits that mediate higher brain functions 
such as object recognition and cognition. 
Even though specific mechanisms of modulation work in each circuit level, 
modulation also spans all levels and a single change at a nanocircuit level may have 
reverberant effects at a macrocircuit level in health and disease. This is the case for 
AHP, which functional role not only regulates neuron electrical excitability but is also 
associated with higher functions, such as memory and learning, and dysfunctions, such 
as epilepsy. 
Through K+ channels, the AHP prevents overexcitation of the neuron in response to 
repetitive or long-lasting stimulus inputs (mAHP and sAHP) (Hille, 2001), determines 
firing frequency (mAHP) and bursting frequency (sAHP) (Gu et al., 2007) and shapes 
firing patterns (sAHP), thus modulating nanocircuit activity. The frequency of firing and 
bursting and the shape of firing patterns assume special roles at a macrocircuit level, in 
network synchronization and higher functions (and dysfunction). A common feature of 
AP firing patterns in vivo is bursting (Kandel and Spencer, 1961; Ranck, 1973; Fox and 
Ranck, 1975; Suzuki and Smith, 1985) and its frequency is regulated by sAHP. The 
sAHP is modulated by activity (amplitude increases with the number of APs fired 
(Hotson and Prince, 1980; Madison and Nicoll, 1984) and neurotransmitters, allowing 
them to alter the firing properties of the neuron (Madison and Nicoll, 1982; Andrade and 
Nicoll 1987; Haas and Konnerth, 1983). It has been shown that sAHP correlates with 
learning and aging (Disterhoft et al., 2004; Oh et al., 2010) and its malfunction is 
implicated in epilepsy (McCormick and Contreras, 2001). 
Neuronal activity coherence and stability lies in a very tightly regulated interaction 
between all levels of networks (nano-, micro- and macrocircuits). This stability may be 
imbalanced by a single mutation in one ion channel, easily leading to a situation of 
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uncontrolled overexcitation or depression. This is especially important in epilepsy, 
which can result from disturbance in all levels of organization, from the biochemical 
level (chanelopathies) to the cell level (specific cell type death) to microcircuit level 
(recurrent excitation), manifested in a macrocircuit level (generalized seizure) (see 
Table 2 for summarized identified causes of epilepsy).  
 
 Table 2. Summarized Functional level abnormalities in Epilepsy 
Level Biological Basis Examples  
Nanocircuit Ion Chanelopathies(1) 
Mutations in sodium(2), calcium(3), potassium(4) 
and ligand-gated channels 
 
Microcircuit 
Abnormal network plasticity and/or  
Changes in the epileptogenic 
substrate/network(5)  
 
 Loss of excitatory neurons “driving” inhibitory 
neurons(6) 
 Loss(7) or mal-development(8) (migration and 
maturation) of interneurons 
 Reactive gliosis 
(e.g. hippocampal sclerosis(9), cortical dysplasia) 
 
Microcircuit 
and 
Macrocircuit 
Seizure-induced synaptic 
reorganization: development of 
epileptic circuits within and 
between brain regions(10) 
Leading to aberrant neuronal 
synchronization(11) 
 Excitatory compensatory axonal sprouting in 
the hippocampus(12) (Microcircuit) 
 Limbic network synchronization(13) 
(Hippocampus, amygdala, entorhinal cortex, 
olfactory cortex and the midline thalamic 
nuclei) (Macrocircuit) 
 Aberrant oscillatory rhythms(14 (by circuits 
connecting the cortex and thalamus – 
Thalamocortical Rhythms) (Macrocircuit) 
 
 
(1) George, 2004 
(2) Meisler et al., 2010   
(3) Gambardella and Labate, 2014 
(4) D’Adamo et al., 2013 
(5) Paz and Huguenard, 2015 
(6) Biagini et al., 2005 
(7) Liu et al., 2014  
(8) Kriegstein, 2005; Powell, 2013 
 
(9) Thom, 2014 
(10) Caciagli, 2014  
(11) Meisel, 2016  
(12) Sutula, 2002  
(13) Jefferys et al., 2012 
(14) Huguenard, 1999 
 
 
 
 
 
 
 
 
 
 
 
23 
 
1.2. Imbalance in neuronal activity: Epilepsy  
Epilepsy is one of the most common serious neurological disorder worldwide with 
no age, racial, social class, national nor geographic boundaries (WHO, 2004). It affects 
0.5-2.0% of the global population (Hauser et al., 1998; Picot et al., 2008) and it is 
estimated that 2.4 million are diagnosed with epilepsy every year (Hirtz et al., 2007).  
Nowadays it is clear that perturbed neuronal activity is in the basis of epilepsy, but 
this is a relatively new concept in the History of mankind. Indeed, epilepsy is an ancient 
disorder, in the sense that it can be traced as far back as medical records exist to the 
medical texts of the Assyrians and Babylonians in the 2000 BC. Since then and until 
recently, epilepsy was seen not as a physical disease but as a spiritual invasion of the 
body by an evil spirit. For this reason, the physical clinical observation of epilepsy was 
named seizure (from the Latin sacire – to take possession of). Even though 
Hippocrates, in 400 BC, had been the first to identify the brain as the physical structure 
affected (in On the Sacred Disease, 400 BC), the idea of epilepsy being a spiritual 
affliction remained unchanged. For this reason, epileptics were treated as lunatics or 
possessed until the 18th and 19th centuries. In the 19th century, electrical neuronal 
activity was declared to be the source of such disorder (Fritsch and Hitzig, 1870; 
Sidiropoulou et al., 2010) but a better understanding of the mechanisms of the disease, 
the development of effective drugs and neurotechnology for a successful yet 
incomplete medical therapeutic only emerged progressively throughout the 20th century 
(for a review see Magiorkinis et al., 2014). 
As pointed out in the previous chapter, Epileptogenesis, the term given to the 
processes that originate epilepsy, encompasses very broad phenomena and it probably 
differs for the various types of epilepsy (Schuele and Lüders, 2008). For this reason, 
many authors consider that many “epilepsies” exist, rather than a single one. This 
reality is also mirrored by the diversity of seizures patients experience, which may be 
categorized by seizure foci (partial or generalized) and type (simple or complex if it is 
partial, and in tonic-clonic, absence, myoclonic and atonic, if generalized). Despite the 
broad epileptogenesis mechanisms, the outcome is the same: seizures - an imbalance 
between excitatory/inhibitory tonus that leads to an abnormal, excessive, 
hypersynchronous neuronal activity in the brain, rendering the individual unable to 
consciously control its body for briefs moments (Goldberg and Coulter, 2013). It can 
vary from uncontrolled jerking movement (tonic-clonic seizure) to as subtle as a 
momentary loss of awareness (absence seizure). Epilepsy is characterized by an 
enduring predisposition to generate epileptic seizures, though seizures can also occur 
sporadically in people who do not have epilepsy (for further reading on Epilesy, see 
Kandar et al., 2012).  
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Despite the broad epileptogenesis mechanisms, successful therapeutic strategies 
employed today counteract the exacerbated neuronal excitability. About two thirds of 
the epileptic patients are successfully treated with antiepileptic drugs (AEDs) that act 
mainly by increasing GABAergic system or blocking Na+ channels, even though other 
AEDs act upon other targets (see Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
Figure 3. Mechanisms of action of clinically approved AEDs. Neuronal activity is decreased 
by interfering with action potential generation (through voltage-gated ion channels: Sodium 
channels blockers, Potassium channels openers and Calcium channel blockers, colored in blue) 
and by interfering with synaptic transmission, either GABAergic system (lower left panel – 
inhibitory synapse, colored in red) or Glutamatergic system (lower right panel – excitatory 
synapse, colored in green). Some AEDs present multiple mechanisms of action, colored in 
orange. (Adapted from Bialer and White, 2010). 
 
1.2.1. Pharmaco-Resistant Epilepsy 
In spite of the availability of different class of anti-epileptics therapies, about one 
third of the patients is pharmacoresistant (Kwan and Brodie, 2000; Sillanpaa et al., 
1998). Despite the discussion around the definition of pharmacoresistance, it is 
nowadays identified when seizure management is not achieved by a first or a second 
anticonvulsivant medication at daily therapeutic dosage (Kwan et al., 2010). 
 
 
Synaptic 
Transmission 
Propagated  
action potential
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Pharmaco-Resistant Epilepsy (PRE) poses a serious threat to global human health 
and wealth since it increases 2 to 10-fold the risk of sudden death when compared to 
the general population (Chapell et al., 2003) and it represents the major socioeconomic 
burden for neurological disorders, estimated in over 3 billion $ in a given year in US 
(Murray et al., 1996), 75% of which is due to indirect expenses, such as loss of 
productivity from unemployment, underemployment or lost work time and lost work of 
relatives and friends, who care for the patient with PRE (Platt and Sperling, 2002). The 
critical aspect of PRE, aside being a medically, physically and social disabling disorder 
(Kwan and Brodie, 2002), is the fact that it is progressive, as Hippocrates stated: “It is 
also curable (…) unless by long lapse of time it be so ingrained as to be more powerful 
than the remedies that are applied.” (in On The Sacred Disease, 400 BC). Nowadays, 
the fact that a minority of patients refractory to currently used drugs may become 
seizure free with new AEDs (Bazil, 2002) seems to indicate that no absolute 
intractability exists. Thus, medically intractable seizures may become tractable, once 
we understand more about the mechanisms underlying intractability and how to prevent 
or reverse this state. 
 
1.2.2. Biological basis for Pharmaco-Resistant Epilepsy 
Pharmacoresistance is not unique to epilepsy: it is now recognized in diverse brain 
disorders, including depression and schizophrenia (Löscher and Potschka, 2005) and 
in other diseases affecting the brain, such as human immunodeficiency virus infection 
and many forms of malignant neoplasias (Siddiqui et al., 2003). As stated by 
Alexopoulos, the failure of multiple AEDs on treating PRE patients points towards a 
dysfunction not specific for a single AED target, but to a higher dysfunction that 
interferes with all AEDs mechanisms of action in general. Hence, the mechanisms of 
PRE are not necessarily the same as those underlying the epileptogenic process per 
se (Granata et al., 2009).  
Different scenarios or patterns of multidrug resistance exist in epilepsy. In many 
patients with medically intractable epilepsy, epilepsy is refractory from the onset (de 
novo resistance), suggesting that intrinsic (constitutive) factors are involved in 
intractability (Arroyo et al., 2002). However, in other patients, drug resistance may arise 
during the course of epilepsy after an initially positive response, suggesting that 
epilepsy-related, acquired changes affecting AED efficacy or progression of the disease 
are involved in intractability (Progressive drug-resistance)(Arroyo et al., 2002). In some 
cases, drug resistance to a specific AED arises after an initially positive response, but 
disappears with a new AED trial (waxing and waning resistance). Thus, any hypothesis 
of multidrug resistance has to deal with these and possibly other patterns in the 
occurrence and course of intractability in epilepsy. 
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Mechanisms in the origin of PRE 
Pharmacoresistance mechanisms still remain to be fully elucidated. The main 
hypotheses that – at least in part – explain pharmacoresistance include the transporter 
hypothesis, the target hypothesis, the network hypothesis, the gene variant hypothesis 
and the intrinsic severity hypothesis (see Table 3.) (Remy and Beck, 2006; Löscher et 
al., 2013; Schmidt and Löscher, 2009). However, none of these hypothesis stands 
alone and is able to convincingly explain how drug resistance arises in human epilepsy 
(Schmidt and Löscher, 2009). Moreover, they are not mutually exclusive and may be 
either constitutive or acquired during the course of the disease (Pati and Alexopoulos, 
2010). 
Table 3. Hypothesis in the basis of Pharmaco-Resistant Epilepsy 
 
Hypothesis 
 
 
Mechanism 
 
 
Clinical proof 
 
Transporter 
Suggests that inadequate penetration of AEDs 
across the blood–brain barrier (caused by increased 
expression of efflux transporters such as P-
glycoprotein and multi-drug resistance proteins 
(MRPs) leads to insufficient drug levels in 
epileptogenic brain tissue. (Löscher and Potschka, 
2005; Schmidt and Löscher, 2005); 
Inhibiting the efflux 
transporter P-glycoprotein 
counteracted resistance to 
AEDs in a rat model of 
pharmacoresistant 
temporal lobe epilepsy 
(Brandt et al., 2006) 
   
Altered 
Target 
Suggests that acquired 
alterations to the structure 
and/or functionality of target 
ion channels and 
neurotransmitter receptors 
lead to insufficient 
pharmacodynamic activity of 
AEDs in the brain; 
A reduced sensitivity of major targets for many of 
the clinically established AEDs (Rogawski and 
Löscher, 2004), such as the voltage-gated 
sodium channel and the GABAA (γ-aminobutyric 
acid type A) receptor, has been suggested to 
have a role in AED-resistant chronic human and 
experimental epilepsy (Schmidt and Löscher, 
2005; Remy and Beck, 2006) 
   
Network 
Proposes that structural brain alterations and/or 
network changes (for example, hippocampal 
sclerosis) are involved in resistance to AEDs; 
Surgical resection of the 
altered network counteracts 
AED resistance and may 
even cure epilepsy (Wiebe 
and Jette, 2012) 
   
Gene 
variant 
Suggests that there is an inherent resistance that is 
governed by genetic variants of proteins that are 
involved in the pharmacokinetics and 
pharmacodynamics of AED activity (Löscher et al. 
2009); 
 
   
Intrinsic 
Severity 
Suggests that an increased disease severity leads to 
drug intractability (Rogawski, 2013). 
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The most common form of pharmaco-resistant epilepsy is Temporal Lobe epilepsy 
(TLE) and is usually associated with hippocampal sclerosis (HS) (Thom, 2014). For 
several decades, HS has been considered the source of the electrical events that cause 
spontaneous seizures (Falconer, 1974). However, HS is found in approximately 40-
65% of patients who undergo surgery for TLE (de Lanerolle et al., 2003), and whether 
hippocampal sclerosis is the cause or the consequence of repeated seizures is still a 
matter of debate (Jefferys, 1999; Boison, 2008).  
Hippocampal sclerosis includes three main features (for a review see Thom, 2014):  
1. Selective loss of neuronal cells (both excitatory and inhibitory) 
2. Axonal sprouting 
3. Gliosis 
The selective loss of inhibitory neurons (interneurons) as long been regarded as a 
primary cause for imbalanced neuronal activity, which applies to both 
pharmacoresistant and pharmacosensitive epilepsies. As mentioned before, inhibitory 
neurons are responsible to control excitability and regulate neuronal communication. 
They comprise a highly heterogeneous class of neurons, with more than 20 types of 
interneurons in the hippocampus with different morphology, molecular expression, axon 
projection and discharge pattern (Liu et al., 2014). Their heterogeneity endows them 
with different properties suited to perform different microcircuit functions (see Figure 4.) 
present in the hippocampus.  
 
 
 
 
 
 
 
 
Figure 4. Microcircuit motifs whose dysfunction have been identified in epilepsy. Feed-
forward inhibition: excitatory inputs from remote brains regions recruit local inhibitory networks 
that control the strength of the efferent signal. Feed-back inhibition: local activation of inhibitory 
neurons controls local recurrent excitatory activity. Counter-inhibition: local connections between 
inhibitory neurons shape network-inhibitory output. Recurrent excitation: major mode of 
connectivity in cortical networks. Purple and red represent excitatory glutamatergic and inhibitory 
GABAergic neurons, respectively. From Paz and Huguenard, 2015. 
 
Selective loss of interneurons leads to microcircuit network destabilization and 
hyperexcitability since this operations (feed-back inhibition and counter inhibition, for 
example) are disrupted. Upon loss of excitatory and inhibitory neurons, occurs an 
attempt of the system to recover the lost wiring circuits, by establishing new synapses 
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with survival neurons. However, this process of axonal sprouting may be unsuccessful 
leading to an abnormal network reorganization which is seen as a cause for 
hyperexcitability in HS. 
Gliosis is another hallmark of HS. It refers to an abnormal morphology and 
function of glia cells (astrocytes, microglia and oligodendrocytes) in response to 
damage. Astrocytes have been recently shown to play an important role in epilepsy 
dysfunction (Binder and Steinhäuser, 2006; Coulter and Steinhäuser, 2015). They 
are involved in many functions that were observed to be dysfunctional in epilepsy, 
namely Blood-Brain Barrier maintenance, homeostasis of extracellular ions, mainly 
K+, adenosinergic system dysfunction, synaptic communication (tripartite synapse) 
and electrical coupling in astrocyte-astrocyte communication (see Table 4.) (Coulter 
and Steinhäuser, 2015). More specifically, investigation of specimens from patients 
with pharmacoresistant temporal lobe epilepsy and epilepsy models revealed 
alterations in expression, localization and function of astroglial K+ and water 
channels, entailing impaired K+ buffering. Moreover, malfunction of glutamate 
transporters and the astrocytic glutamate-converting 
enzyme, glutamine synthetase, as observed in epileptic tissue, suggested 
that astrocyte dysfunction is causative of hyperexcitation, seizure spread and 
neurotoxicity (Coulter and Steinhäuser, 2015). Even though it is not clear yet 
whether gliosis is a cause or consequence of epileptic activity, it is in a special 
position to explain pharmacoresistance mechanism hypothesis, common to different 
patients. 
Table 4. Astrocyte (Dys)Function in Epilepsy 
(1) Seiffert et al., 2004; Ivens et al., 2007; Tomkins et al., 2007 
Physiological function Epilepsy Example 
   
Trafficking of substances 
from BBB to neurons 
Compromised Blood–brain 
barrier (BBB) (1)  
Long-lasting breakdown of the (BBB) leads 
to astrocyte GFAP upregulation, followed by 
development of an epileptic focus(2) 
   
   
Homeostasis of extracellular 
ions, principally potassium 
 Activity-dependent shifts in 
ion concentrations contributes 
to ictogenesis(3) 
Tetanic stimulation of afferents as well as 
chemically induced seizure activity 
increases K+o, compromising the resting 
membrane potential of neurons and 
cotransport of other ions(4) 
   
   
Homeostasis of extracellular 
adenosine concentration by 
adenosine kinase ADK 
Dysfunction in adenosinergic 
system has been associated 
with epilepsy(5) 
Mice overexpression of ADK are prone to 
seizures and exhibit cognitive impairments 
seen in epilepsy(5) 
Decreased A1R is associated with epilepsy(6) 
   
   
Astrocyte-Astrocyte 
communication 
Disruption of Astrocyte-
Astrocyte communication 
Electrical coupling between astrocytes is 
disrupted in TLE patients(7) 
   
(2)  David et al., 2009 
(3)  Fisher et al., 1976; Staley et al., 1995; Raimondo et al., 2013 
(4)  Ransom et al., 2000 
 
(5)  Boison, 2008 
(6)  Boison, 2012b 
(7)  Steinhäuser et al, 2012 
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 1.2.3. Treatment for Pharmaco-Resistant Epilepsy 
In Pharmaco-Resistant Epilepsy, AEDs are not able to render the patient seizure-
free. For this reason, other pharmacological and non-pharmacological treatments are 
applied (see Table 5) (Sharma et al., 2015). 
From the non-pharmacological treatments, surgical procedures are the most widely 
applied whenever possible and have been successful in 65% of the cases (Wiebe and 
Jette, 2012). However, it is often not possible to proceed that way and other 
pharmacological and non-pharmacological procedures are applied. 
From the pharmacological treatments, one of them is considered to be an 
endogenous inhibitory mechanism that is triggered by elevated network activity: 
adenosine. Studying it is a promising strategy for developing anti-epileptic strategies 
(Löscher and Kohling, 2010). 
Table 5. Main Treatments for Pharmaco-Resistant Epilepsy 
 Treatment Examples 
   
P
h
a
rm
a
c
o
lo
g
ic
a
l 
Add-on drug to treat pharmaco-
resistance mechanism (e.g. the 
transporter hypothesis) 
 
 Verapamil, a P-gp inhibitor that avoids AED 
transport efflux, in conjuction with an AED 
(Carbamazepine) 
 
  
Neuromodulators with protective 
endogenous properties 
 Neuropeptide Y 
 Adenosine 
  
Others molecules presenting 
antiexcitotoxicity, anticonvulsivant and 
neuroprotective properties 
 Atorvastatin 
 Thyrotropin-releasing hormone 
 
  
N
o
n
-P
h
a
rm
a
c
o
lo
g
ic
a
l 
Surgical procedures: 
 Seizure foci removal 
 
 Anteromedial temporal lobectomy 
 Focal neocortical resection 
 Lesional resection 
 Hemispherectomy 
  
 or Disconnection 
 Corpus callosotomy 
 Multiple subpial transections 
  
Neurostimulation 
 
 Vagal nerve stimulation 
 Responsive neurostimulation 
 Thalamic stimulation 
 Transcranial stimulation 
  
Dietary Therapies 
 
Promote production of endogenous 
anticonvulsivant molecules, as adenosine 
and GABA, since ketonebodies processing is 
different between brain and liver of epileptic 
patients 
 Classic ketogenic diet 
 Medium chain triglyceride  
 Modified Atkins diet 
 Low glycemic index treatment 
  
Focal cooling 
Rapid cooling of the brain reduces epileptiform 
activity and may also terminate focal seizures 
  
Herbal remedies Cannabinoids 
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1.3. Adenosine as a solution for Pharmaco-Resistant Epilepsy 
Exploring endogenous inhibitory mechanisms is a nature-based approach to try to 
answer pharmaco-resistant epilepsy. One endogenous anticonvulsivant mechanism 
is the seizure-induced release of the neuromodulator adenosine.  
Before going deeper into adenosine anticonvulsivant properties, it is important to 
integrate adenosine in its biological and biochemistry roles. Adenosine is a purine 
ribonucleoside (Figure 5.), one of the building blocks of life from an evolutionary and 
structural point of view. It was likely part of the ‘‘primordial soup’’ at the origin of life on 
Earth (Oro, 1961). Therefore it is not surprising that adenosine is an integral 
component of compounds essential for basic biochemistry and mitochondrial 
bioenergetics, such as energy transfer (ATP and ADP), nucleic acid structure (DNA 
and RNA (including poly-A tails), intracellular signaling (cAMP) and others. Therefore, 
it is an ubiquitous molecule present in all cells. Later on, in evolution, adenosine roles 
spanned over a wider range of functions (Dunwiddie and Masino, 2001), including the 
cardiovascular system, the immune system, the gastrointestinal tract and the nervous 
system, which is of particular interest in the context of pharmaco-resistant epilepsy.  
Adenosine role as an endogenous modulator of neuronal excitability took more 
than 50 years to be stablished (Dunwiddie and Hoffer, 1980; Fredholm and Hedqvist, 
1980) after the first observation from Drury and Szent- Györgyi (1929). Nowadays, its 
relevance in the sleep/arousal system, cognition and memory, neuronal maturation 
and development (Ribeiro et al., 2002) is well recognized such as its neuroprotective 
and anticonvulsivant properties (Boison et al., 2010; Fredholm et al., 2005a; Ribeiro, 
2005; Stone et al., 2009).  
 
 
Figure 5. Adenosine chemical structure. 
Adenosine is composed by a purine, adenine (in 
orange), linked to ribose (in black) by a C1’-N9 
glycosidic bond.  
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1.3.1. Neuromodulation by Adenosine 
 Being a neuromodulator, adenosine modulates the cellular properties of pre- 
and/or postsynaptic neurons (or glial cells) and regulates synaptic transmission and 
plasticity, neuronal networks and behavior (Kaczmarek and Levitan, 1987).  
Its role in neuromodulation is triggered by neuronal activity and depends on its 
release to the extracellular space (Figure 6.). Adenosine is either directly released by 
neurons or glia (through adenosine equilibrative transporters) or, most frequently, 
originated extracellularly from released ATP, by neurons and glia, converted into 
adenosine  by a cascade of ectoenzymes (Richardson et al., 1987; Terrian et al., 1989; 
White and MacDonald, 1990; Dunwididie et al., 1997; Zimmermann et al., 2012). 
Extracellular ATP from astrocytes is possibly the major contributor of external 
adenosine concentration in physiological conditions, as confirmed in the hippocampus 
(Cunha et al., 1996a, Koizumi et al., 2003; Newman, 2003, Pascual et al; 2005). 
Regulation of extracellular adenosine concentration is critical to healthy 
neuromodulation and is severely perturbed in epilepsy, which will be discussed further 
on. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Adenosine sources and receptors. Extracellular adenosine can result from 
1. Direct release (through adenosine equilibrative transport) or 2. Indirectly from 
extracellular ATP hydrolysis (by a cascade of ectoenzymes). Extracellular ATP sources 
may be: ATP co-release from neurotransmitter-filled vesicles (pre-synaptic neuron), ATP 
vesicular release from astrocytes and ATP release from channels (connexin 
hemichannels or pannexin channels, not depicted). Extracellular adenosine exert its 
neuromodulatory role through receptor-dependent mechanisms, activating adenosine 
receptors (ARs). Intracellular metabolism of adenosine nucleotides is not shown such as 
extracellular degradation. Legend: ABC: ATP-binding cassette (ABC) transporters; ENT: 
Equilibrative Nucleoside Transporters; Ecto-PDE: Ectophosphodiesterase; NT5E: ecto- 
5′-nucleotidase; NTPDase: ecto-nucleoside triphosphate diphosphohydrolase. 
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Once in the extracellular space, adenosine can influence neurotransmission by 
acting directly onto neurons, either pre-, post- or peri/extra-synaptically, or onto non-
neuron cells by influencing glia function. It acts through receptor-dependent and 
independent mechanisms. Receptor-dependent mechanisms are known to modulate 
neurotransmitter release machinery, other ionotropic or metabotropic receptors, 
transporters or control of function of other neuronal modulators (Ribeiro and Sebastião, 
2010). Receptor-independent mechanisms are less studied and involve 
transmethylation and epigenetics, mitochondrial bioenergetics and additional 
biochemical pathways (Boison, 2012b; Boison, 2016). 
Focusing on receptor-dependent mechanisms, adenosine acts via four known 
guanine-binding protein (G-protein)-coupled adenosine receptors (ARs): adenosine 
receptor type 1, 2A, 2B and 3 (A1R, A2AR, A2BR and A3R, respectively) (Boison and 
Stewart, 2009; Fredholm et al. 2001, 2011) (Figure 7.). These receptors have a 
distinctive pharmacological profile, tissue distribution and effector coupling, and its 
functioning has been extensively studied in the CNS (see Table 6.). In basal 
physiological conditions, the intracellular concentration of adenosine is estimated to be 
less than 50 nM, whereas the extracellular synaptic concentration of adenosine ranges 
from 25 to 250 nM (Ballarín et al., 1991, Dunwiddie and Diao, 1994) with small variations 
in-between brain regions (Delaney and Geiger, 1996). This is sufficient to activate A1 
and A2A receptors in a physiological condition, but not A2B and A3 receptors, which 
require higher agonist concentrations thus seen as more relevant in a pathological 
scenario. 
As described before, these receptors can be grouped by affinity: A1R and A2AR are 
high-affinity receptors, which have higher physiological relevance, while A2BR and A3R 
are low-affinity receptors, gaining more relevance in a pathological scenario. ARs can 
also be grouped by function: activation of A1 receptors leads to an inhibition of synaptic 
transmission and neuronal excitability, while activation of A2A and A2B receptors leads 
to an increase in neurotransmitter release and excitation (Sebastião and Ribeiro, 1996). 
The properties of A3 receptors in the brain are still not well understood (Jacobson, 
1998). It is important to note that A3Rs display high affinity for adenosine in humans, 
unlike what occurs in the rat (Fredholm et al., 2001), but have a low density in most 
tissues in humans (Ribeiro et al., 2003). 
In Figure 7., ARs activation is depicted along with its main signaling pathways 
and effects. Of special interest in the context of seizure arrest is A1R, due to its 
function, density and distribution. 
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Figure 7. Adenosine receptor 
signaling. Adenosine receptors are 
G-coupled proteins negatively (A1R, 
A3R) or positively (A2AR, A2BR) 
coupled to adenylate cyclase (AD). 
Inhibition of AD leads to lower cAMP 
concentrations, which prevents 
protein kinase from phosphorylate 
Ca2+ channels, a step required for 
Ca2+ influx. A1R and A3R also directly 
potentiate potassium channels 
opening. A2AR and A2BR potentiate AD 
activity, leading to increased Ca2+ 
influx, which is necessary for neurotransmitter vesicle release synchronization, augmenting 
the signal in the synapse, therefore being called excitatory. From Ham and Evans, 2012. 
 
Table 6. Adenosine receptor characterization in the CNS 
Receptor Type A1R A2AR A2BR A3R 
Adenosine 
Affinity  
70 nM  150 nM 5100 nM 6500 nM  
G-protein 
coupling  
Gi and G0 Gs and Golf Gs Gi3 and Gq  
Transduction 
Mechanisms  
Inhibits AC 
Inhibits Ca2+ 
channels 
Activates GIRKs 
Activates PLC 
Activates AC 
Activates Ca2+ 
channels 
 Inhibits Ca2+ 
channels 
Activates AC 
Activates PLC 
Inhibits AC  
Activates PLC 
Increases 
intracellular Ca2+ 
Physiological 
Actions  
Inhibits synaptic 
transmission 
Hyperpolarizes 
neurons 
Facilitates 
transmitter release  
Inhibits transmitter 
release 
Increases cAMP 
in brain slices 
Modulation of 
Ca2+ channel 
function 
Inhibits A1R 
mediated 
responses (1) 
 Inhibits mGluR 
mediated 
responses(2);  
High Abundance  
Hippocampus  
Neocortex 
Cerebellum 
Spinal cord 
Striatum 
Olfatory bulb 
- - 
Medium/Low 
Abundance  
Amygdala   
Olfatory bulb 
Striatum 
Thalamus 
Substancia nigra 
Hippocampus 
Neocortex 
Thalamus 
Uniform low level 
of expression 
Hippocampus  
Cerebellum 
Legend: AC: adenylate cyclase; GIRKs: G-protein–dependent inwardly rectifying K+ channels; 
mGluR: metabotropic glutamate receptor; PLC: phospholipase C. (1) (Dunwiddie et al. 1997); 
(2) (Macek et al. 1998); Adapted from (Dunwiddie and Masino, 2001; Boison 2005). 
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1.3.2. Endogenous anticonvulsivant mechanisms of Adenosine 
Activation of A1R is considered an inhibitory biological endogenous mechanism, 
which inhibits network excitability, limits the extension of seizures and mediates seizure 
arrest (Etherington and Frenguelli, 2004; Fedele et al., 2006; Li et al., 2007). A1R is 
widely distributed in CNS with prominent abundance in the hippocampus, cerebral 
cortex, cerebellum and dorsal horn of spinal cord (Goodman and Synder, 1982; Mahan 
et al., 1991; Reppert et al., 1991; Ribeiro et al., 2003) (Table 6). It can be found 
heterogeneously expressed within neurons in the pre- and postsynaptic density (Rebola 
et al., 2003) as well as in non-neuronal cells such as astrocytes (Biber et al., 1997), 
microglia (Gebicke-Haerter et al., 1996) and oligodendrocytes (Othman et al., 2003).  
The coupling of A1Rs to Gi/G0 proteins underlies several mechanisms by which 
adenosine can modulate synaptic transmission (Dunwiddie and Masino, 2001), both 
glutamatergic and GABAergic transmission. 
In the case of glutamatergic transmission, presynaptic activation of A1Rs causes 
decreased neurotransmitter release (Figure 8. A) (Fredholm and Dunwiddie, 1988). 
This is mediated by inhibition of adenylyl cyclase (van Calker et al., 1979), PKA 
decreased activity and consequent reduction in neurotransmitter release probability by 
inhibiting calcium (Ca2+) influx through voltage-gated channels (MacDonald et al., 1986; 
Schubert et al. 1986; Barrie and Nicholls, 1993; Yawo and Chuhma, 1993; Ribeiro 1995; 
Wu and Saggan, 1994; Cunha, 2001; Gundlfinger et al., 2007), or by interfering directly 
with the release process (Scanziani et al., 1992; Thompson et al., 1993). At the same 
time, adenosine has been shown to function post-synaptically (Figure 8. B), which 
results in resting membrane potential hyperpolarization (Ponce et al. 1996, Ehrengruber 
et al. 1997), through activation of a series of downstream potassium (K+) channels, 
including G-protein-coupled, inward-rectifying K+ channels (GIRKS) (Segal, 1982; 
Greene and Haas, 1985; Trussell and Jackson, 1985; Gerber et al. 1989) and control 
burst-like activity in CNS (Dragunow, 1988). During seizures, A1R-dependent activation 
of potassium channels increase the cell membrane conductance and has a shunting 
effect on GABAAR currents, significantly attenuating the depolarizing GABAAR 
responses and also reducing the extent of the after-discharge phase of the seizure (Ilie 
et al. 2012). 
A1R activation also reduces long-term changes in synaptic efficiency (de Mendonça 
and Ribeiro, 1997), activates phospholipase C (PLC)/Protein kinase C (PKC) pathway 
(Kendall and Hill, 1988) and can also modulate the excitatory effects of post-synaptic 
glutamate receptors (Takigawa and Alzheimer, 2002). It has been observed that A1R 
activation induces AMPAR internalization and long-lasting synaptic inhibition in rat 
hippocampal CA3-CA1 synapses (Chen et al, 2014). In addition to these synaptic effects, 
A1 receptors are believed to provide beneficial extra-synaptic effects, which are based on 
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a decrease in brain metabolism (Haberg et al., 2000) and the control of astrocyte function 
(see van Calker and Biber, 2005).  
These neuromodulatory A1R actions result in a reduction of neuronal excitability and 
constitute an important neuroprotective role of adenosine during excitotoxic events such 
as hypoxia/ischemia or increased neuronal firing (de Mendonça et al. 2000). 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 8. Adenosine anticonvulsivant mechanisms through A1R activation.  
A.  Pre-synaptic A1R activation leads to decreased neurotransmitter release while B. Post-
synaptic A1R activation leads to membrane hyperpolarization, both contributing to decreased 
neuronal excitability. 
 
In the case of GABAergic transmission, there is substantial evidence pointing 
towards a lack of effect of A1R activation on hippocampal phasic GABAergic 
transmission (Dolphin and Archer 1983; Lambert and Teyler, 1991; Yoon and 
Rothman, 1991; Cunha and Ribeiro 2000a; Rombo et al., 2014). Despite the absence 
of direct A1R modulation on phasic GABA communication in adult hippocampus 
(pyramidal cells and interneurons), it has been shown that A1R activation suppresses 
tonic GABAA currents in hippocampal pyramidal cells and also in CB1R+/CCK+ 
interneurons (not in CB1-/CCK- interneurons) (Rombo et al., 2016). Suppression of 
tonic GABAA currents leads to increased synaptic transmission. In pyramidal cells, it 
may be a protection mechanism to prevent pyramidal cell shutdown when A1R 
activation is high. In interneurons, increased synaptic transmission implies increased 
inhibition of pyramidal cells (Figure 9), contributing to an A1R-mediated inhibitory role.  
 
 
 
 
A B 
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Figure 9. A1R-mediated action upon GABAergic 
transmission into CA1 pyramidal cells and 
interneurons. Adapted from Rombo et al., 2016. 
 
Tonic but not phasic GABAergic transmission modulation by adenosine may be a 
protective mechanism: phasic transmission can occur “normally” but there is an 
increased inhibitory tonus of the system, which decreases the probability of a seizure 
onset, in the case of uncontrolled firing activity. 
Other receptor systems, commonly associated with the control of GABA responses, 
are also influenced by A1R activation, such as CB1R-mediated control of GABA release 
(Sousa et al., 2011) and enhancement of GABA released caused by vasoactive 
intestinal peptide (VIP) in hippocampal nerve terminals (Cunha-Reis et al. 2008).  
These regulatory mechanisms of A1R are consistent with the neuroprotective 
actions of adenosine in the adult brain and may confer an important developmental 
control of excitation during neuronal maturation.  
In contrast to A1 receptors, A2A receptors are coupled to stimulatory Gs proteins - 
increasing adenylate cyclase activity and raising intracellular levels of cAMP - or Golf 
proteins (Corvol et al., 2001). They have a much more restricted distribution in the 
brain (see Ribeiro et al., 2003), being characteristic of dopamine enriched areas (e.g.: 
striatum) (Svenningsson et al., 1997). In the hippocampus, A2A receptors have been 
shown to increase synaptic transmission and excitability (Sebastião and Ribeiro, 
1992; Cunha et al., 1994a), synaptic plasticity (de Mendonça and Ribeiro, 1994) and 
the evoked release of acetylcholine (Cunha et al., 1994b), glutamate (Lopes et al., 
1999) and GABA (Cunha and Ribeiro, 2000). Less is known about the contribution of 
the low-affinity A2B and the low-density A3 receptors. Given the low-affinity of A2B 
receptors for adenosine, it is suggested that they have an important role in 
pathological conditions when extracellular adenosine concentration rises (see 
Fredholm, 1997).  
The A3 receptors are found mostly in peripheral tissues and have been extensively 
studied in cells from the immune system (e.g. Rankumar et al., 1993). In the brain, its 
role is still controversial. 
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1.3.3. Adenosine (Dys)Function in Epilepsy 
 
The endogenous inhibition of neuronal excitability by adenosine depends on the 
level of adenosine as well as the expression level of receptor subtypes in a given cell 
type or subregion of the brain. Bearing this in mind, it becomes easy to understand 
that neuroprotection through A1R activation may fail if there is 1. low adenosine in the 
extracellular space or 2. low A1R density. In fact, it has been observed that, in epilepsy, 
the adenosinergic system is dysfunctional in these two main conditions and its repair 
is sufficient to protect against seizures (see Table 7). Low adenosine levels in the 
extracellular space are largely due to a failure of astrocyte–based adenosine-cycle. 
Astrocytes are the major responsible for extracellular adenosine levels regulation, 
both in providing (through ATP) and re-uptaking adenosine, regulated by intracellular 
astrocytic adenosine kinase (ADK; EC 2.7.1.20) (a phosphotransferase that converts 
adenosine into adenosine-5’-monophosphate (AMP). In pharmaco-resistant epilepsy, 
astrogliosis is one of the hallmarks and impaired adenosine levels regulation 
strengthens the importance of astrocytes in adenosine dysfunction in epilepsy.  
Focusing in pharmacoresistant-epilepsy, adenosine brings hope since it was 
shown to successfully suppress pharmacoresistant seizures (Gouder et al. 2003). 
Adenosine is a special candidate for pharmacoresistant epilepsy since it is an 
endogenous molecule, so it is not expectable to be a substrate for drug efflux. 
 
Table 7. Adenosine (Dys)Function in Epilepsy 
Epilepsy 
Function Dysfunction Repair 
After the onset of a seizure,  
↑ Adenosine levels remain 
elevated postically to activate 
A1R as an endogenous 
anticonvulsivant mechanism(1) 
to prevent further seizure 
development and/or 
propagation 
↓ A1R density(2) 
↑ A1R density and mRNA(3) 
A1R activation(8) 
↑ A2AR mRNA(4) 
↓↑ A2AR mRNA(5) 
A2AR activation (not clear since 
some studies show it can 
suppress(9)  or promote(10) seizures) 
ADK overexpression(6) ADK inhibition(11) 
Astrogliosis(7) ↑ Adenosine levels (by AATs)(12) 
(1) Maitre et al., 1974; Winn et al; 1979; Dunwiddie, 1980; Snyder et al., 1981; Dunwiddie and Worth, 
1982; Burley and Ferrendelli, 1984; Haas and Greene, 1984; Haas et al., 1984; Lee et al., 1984; 
Szot and Murray, 1984; During and Spencer, 1992; Berman et al., 2000; Pedata et al., 2001; de 
Mendonça et al., 2000  
(2) Glass et al., 1996; Ochiishi et al. 1999; Ekonomou et al; 2000; Rebola et al., 2003a,b; Rebola et 
al., 2005; Li et al., 2007 
(3) Angelatou et al., 1991; Angelatou et al., 1993; Pagonopoulou et al., 1993; Psarropoulou et al. 1994; 
Vanore et al., 2001; Aden et al., 2004; Tchekalarova et al., 2005 
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(4) Rebola et al., 2005 
(5) Aden et al., 2004 
(6) Gouder et al. 2004; Shen et al. 2011; Li et al., 2008; Aronica et al., 2011; Masino et al., 2011 
(7)  Gouder et al. 2004; Tian et al., 2005; Binder and Steinhauser, 2006; Boison, 2008  
(8) Barraco et al., 1984; Young and Dragunow, 1994; Rauce and Rüthrich, 1995; Gouder et al., 2003; 
Fedele et al., 2006 
(9) Sarro et al., 1999; Huber et al., 2002 
(10) Zeraati et al., 2006; Hosseinmardi et al., 2007  
(11) Gouder et al. 2004  
(12) Boison, 2009 
 
However, treatment of PRE with adenosine or its analogues is clinically limited due 
to strong systemic side effects, mainly peripheral cardiovascular (slowing of the heart 
beat, vasoconstriction) (Monopoli et al, 1994; Gouder et al, 2013). Inhibition of 
cardiovascular activity is so relevant that adenosine is clinically administered as an 
antiarrhythmic in the short pharmacological treatment of paroxysmal supraventricular 
tachycardia (elevated heart rate) (Riccardi et al., 2008). For this reason, focal delivery 
of adenosine into the brain has been pursued with many techniques now developed 
and tested in animal models. They are called Adenosine Augmentation Therapies and 
can be divided into three main groups: 1. Polymer-based adenosine deliver (ethylene 
vinyl acetate copolymers, silk-based polymers), 2. Encapsulated cell systems 
(encapsulated fibroblasts, encapsulated myoblasts) and 3. Stem cells (mouse 
embryonic stem cells, human mesenchymal stem cells) (Boison, 2009a,b, 2012a). 
Despite being successful, focal therapies still imply a major economic cost (in 
development and application) and feasibility (surgery), when compared to adenosine 
systemic administration. 
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1.3.4. MRS5474 – a new promising adenosine derivative  
If an orally administered drug could act as an A1R agonist without its known the side 
effects, that would be ideal. To do so, it would be necessary to develop an adenosine 
derivative selective towards the central nervous system, instead of the peripheral system. 
Exploring a target specific mechanism that only happens in the CNS could be an answer 
(for example, the specific modulation of tonic GABAAR conductance of a subset of 
interneurons by A1R activation (Rombo et al. 2016).   
With this goal, many adenosine derivatives have been developed and characterized 
in the past (reviewed by Jacobson et al., 1992). Recently, Kenneth Jacobson’s team 
derived adenosine analogues by N6-methanocarbon substitution of 4’-truncated 
adenosine and screened for human A1R, A2AR and A3R selectivity, affinity and full 
agonism (Tosh et al., 2012). The goal was to design a selective and potent human A1R 
agonist to be used in various conditions treatment, including epilepsy. Upon in vitro 
testing for selectivity, affinity and full agonism, one adenosine derivative, MRS5474 (2-
Chloro-N6-dicyclopropylmethyl-4′-truncated(N)-methanocarba-adenosine), was selected 
as the most promising candidate to in vivo testing along with a classical highly selective 
A1R agonist CCPA (2-Chloro-N6-cyclopentyladenosine) (Ki=0.4 nM) (Lohse et al. 1988; 
Alnouri et al., 2015). 
MRS5474 (Figure 10.) is described as a moderately selective A1R-full agonist. 
MRS5474 affinity to hARs was assessed by radioligand binding assays: the inhibition 
constant (Ki) of MRS5474, relative to the binding of selective AR agonists to human AR 
stably expressed, is shown in Table 8. MRS5474 presented high affinity for hA1R (Ki = 
47.9 ± 10.5 nM), 10 fold-selectivity for hA1R compared to hA3R, and low affinity to hA2AR 
(Ki = 3950 ± 410 nM). hA2BR was not included in the initial pharmacological screen since 
activity within the class of (N)-methanocarba nucleosides was previously noted to be very 
weak or absent at the hA2BAR (Jacobson, 2000; Tosh et al., 2012b). Functionally, 
MRS5474 was observed to be a full agonist, with hA1R-mediated adenylyl cyclase activity 
comparable to CCPA (94.3±5.3%), as measured by cAMP production. Later, MRS5474 
affinity to hA2BR was studied through the same functional assay. MRS5474 was observed 
to be nearly inactive through hA2BR when compared to the non-selective AR agonist 
NECA (10 µM) (13.7±4.4%). Thus, the A1R selectivity of MRS5474 was maintained within 
the entire AR family. 
 
 
Figure 10 Adenosine derivative MRS5474 chemical 
structure (N6-dicyclopropylmethyl-4′-truncated(N)-
methanocarba-adenosine). Adenosine backbone is 
colored in black (gray for 4’truncated group) and N6-
substitution colored in orange.  
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Table 8. MRS5474 properties as a promising hA1R agonist 
Property hA1R hA3R hA2AR hA2BR 
Ki (nM)a 47.9±10.5 470±15 3950±410 nd 
Affinity High 
Moderately
-Low 
Low 
Very weak or absent in 
within the class of (N)-
methanocarba nucleosidesc 
Selectivity 
10-fold more selective to 
hA1R than hA3R 
Not selective 
Full agonismb 
94.3±5.3% 
Compared to CCPA 
  
13.7±4.4 
Compared to NECA 
Legend: 
nd – not determined 
a - Determined by radioligand binding assays; hAR radioligands: hA1R: [3H]R-PIA, hA2AR: 
[3H]CGS21680, hA3R: [125I]-AB-MECA; NECA as non-specific hAR agonist, and 
membrane preparations from Chinese hamster ovary (CHO) cells (A1R and A3R) or 
human embryonic kidney (HEK) 293 cells (A2AR) stably expressing a hAR subtype; 
b – Functional data determined at a single concentration (10 μM) in an assay of adenylate 
cyclase (A1R-induced inhibition of cyclic AMP production was the final measure in 
CHO cells stably expressing the receptor, standard full agonist used: CCPA) 
c - Activity within the class of (N)-methanocarba nucleosides was previously noted to be 
very weak or absent at the hA2BAR (Jacobson, 2000; Tosh et al 2012b). Adapted from 
Tosh et al. 2012a 
 
Moderate selectivity, high affinity and full agonism (compared to CCPA) of hA1R by 
MRS5474 made it a promising candidate to test its anticonvulsivant properties in vivo 
in a pharmaco-resistant model of epilepsy along with other classical epilepsy models. It 
is important to note that MRS5474 binding properties where studied in human ARs. On 
one hand, it increases translational power since the final goal is to know how MRS5474 
interacts with ARs to produce an antiepileptic effect in humans. On the other hand, in 
vivo testing is not performed in humans in this phase, but rather on rodents, and 
adenosine receptors pharmacological properties are species-dependent (Alnouri et al. 
2015). 
In vivo  anticonvulsivant testing 
MRS5474 was tested in electrical-induced (6 Hz and Maximal Electrical Shock 
(MES) model) and chemically-induced (subcutaneous administration of metrazol 
(pentylenetetrazol) (scMET) model) models of epilepsy in kindled adult male (CF-1) 
albino mice along with a classical A1R agonist CCPA. Toxicity of the drug was 
measured through the rotarod test (considered toxic if the mice fell more than 3 times 
per 1 minute) and named behavioral toxicity. Performance of MRSS5474 in both 
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aspects (anticonvulsivant properties and behavioral toxicity) make it an interesting drug 
for treatment of pharmaco-resistant epilepsy. 
MRS5474 displayed efficacy in a pharmaco-resistant model of epilepsy, 6 Hz, in 
mice (Table 9.): at dose 2.74 mg/kg half the animals were protected against provoked 
seizure. Interestingly, the toxicity observed in A1R activation with selective agonists as 
CCPA was not observed with MRS5474 in the active dose range, around 3 mg/kg, nor 
up to the tested dose of 30 mg/kg, administered intraperitoneally. The therapeutical 
window for MRS5474 is thus wider than compared with CCPA. At dose of 0.12 mg/kg 
of CCPA, half the animals were protected, but behavioral toxicity was seen at 0.84 
mg/kg. Not only the relation of toxicity dose/effector dose is higher for MRS5474 (>10 
in MRS5474, 7 in CCPA) but the dose administration admitted error is bigger in 
MRS5474 since we are dealing with higher doses. At a similar dose that provided 
protection against a provoked seizure for half the animals in 6 Hz model, both CCPA 
and MRS5474 were not able to protect the animals against a provoked seizure in both 
MES model and scMET model.  
 
Table 9. Anticonvulsivant activity in mice of A1R agonists 
 
aadministered i.p. 
bqualitative results, expressed as number of animals protected from convulsions 
cmeasured at 1 h (time of peak of effect) post injection, dose range for MRS5474 was 0.75 
– 10 mg/kg 
dNo rotarod toxicity at 30 mg/kg. Toxicity index (TD50) was defined as the dose at which half 
the animals would fall more than 3 times per 1 minute in the rotarod test.  
 
The 6 Hz and MES model are electrically-induced epilepsy models, where the mice 
are kindling (shocked with electrical shocks in the cornea for 1 week until development 
of epileptic status, under ethical conditions). The authors did not consider absence (or 
near absence) of anticonvulsivant effect in MES model and scMET model (traditional 
epilepsy models) a discouraging property of MRS5474. On the contrary, they agree the 
unique response profile of MRS5474 (inactive in MES and scMET, active in 6 Hz and 
corneal kindling models) and its A1R binding properties make it a potential candidate to 
treat drug-resistant epilepsy. Traditional anti-epileptic drugs (AEDs) carbamazepine, 
lamotrigine, phenytoin and topiramate are Na+ channel blockers, which have strong 
efficacy in the MES model (White et al., 2002). They are either inactive or only partially 
Compounda 
Behavioral toxicity 
TD50 (mg/kg) 
6 Hz model 
ED50 (mg/kg) 
MES modelb 
(dose) 
scMETb 
model (dose) 
MRS5474 >30d 2.74c 
1 out of 4 
(3 mg/kg) 
No protection 
(3 mg/kg) 
CCPA 0.84c 0.12c 
1 out of 4 
(1 mg/kg) 
1 out of 4  
(1 mg/kg) 
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efficacious in the 6 Hz model. On the other hand, newer AEDs having different 
mechanisms of action, such as levetiracetam and retigabine, are potent and efficacious 
in the 6Hz model, which makes the 6 Hz model a model for identifying compounds that 
potentially target drug-resistant epilepsy (Barton et al., 2001). The kindling models are 
useful in searching for drugs to treat complex partial seizures, because kindled seizures 
not only provide an experimental model of focal seizures but also a means of testing 
drugs to stop seizure spread and generalization from a focus (Lothman et al., 1988).  
Even though the analysis for behavioral toxicity is a very broad one (only analyses 
the motor activity on the rotarod), the fact that CCPA has impaired the overall physical 
performance of the mice and MRS5474 did not poses a very interesting case to figure 
out why MRS5474 presents an in vivo antiepileptic role without the A1R activation typical 
side effects. 
The unique activities of MRS5474 in the 6Hz and corneal kindled mouse model and 
its overcoming the limitations of other A1R agonists (i.e. clear separation of 
anticonvulsant activity and toxicity) make it an attractive AED candidate for additional 
testing. 
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1.4. The Hippocampus: a model for antiepileptic drug testing 
To stablish the synaptic target of a putative therapeutic drug, as MRS5474, a suited 
model needs to be chosen. The hippocampus is a very interesting brain structure, not 
only for this specific work, but also for many others since “[it] has something for 
everyone” (Andersen et al., 2007).  
Indeed, the hippocampus provides a unique framework to study processes of varying 
level, ranging from the biochemical characterization of cell biological machinery, 
neurotransmitter receptors and ion channels to processes as synaptic transmission, 
neuronal plasticity, neurogenesis and higher level functions that result from micro- and 
macro-circuitry as memory and behavior. The basis of neurological conditions such as 
epilepsy or Alzheimer’s disease can also be studied in the hippocampus, since it is a 
brain area where pathological processes, as hippocampal sclerosis, occur. Its cellular 
arrangement in defined layers captured the attention of early scientists and facilitates 
structural analyses since different neuronal cells and connections are easily pinpointed, 
which is not the case for other brain regions as the cortex. Moreover, studying the 
hippocampus has provided general concepts of neural functioning (e.g., the neuron 
doctrine) that also apply in other areas of the central nervous system, making it a robust 
model for Neuroscience research.  
For these reasons, the pyramidal neurons of the hippocampus have become the 
most intensively studied neurons in the brain. In this project, our focus lies in 
understanding how MRS5474 is able to change excitatory synaptic transmission in the 
excitatory neurons at the hippocampus. This is a first step to then later evaluate 
evaluate how MRS5474 changes excitatory and inhibitory synaptic transmission of 
inhibitory neurons (interneurons) in a physiological and pathophysiological state. To 
better understand the model used herein, hippocampal structure and circuitry will be 
briefly described, setting the ground for CA1 pyramidal neurons and interneurons 
electrophysiological properties to be focused upon alongside with synaptic and action 
potentials. It is necessary, however, to highlight the limitations of the used model in this 
work: acute hippocampal slices, when comparing and inferring from the obtained 
results. 
 
1.4.1. Hippocampal anatomy and circuitry 
From the beginning of brain research, the hippocampus has played a central role. 
Its elegant and curved structure, visible even to the ancient anatomists, captured their 
attention. The term hippocampus (Latin for seahorse, derived from the Greek word 
hippos meaning “horse” and kampos meaning “sea monster”) was coined by the 
anatomist Giulio Cesare Aranzi, in 1587, because of its similarity to the tropical fish 
seahorse (Figure 11. Center). Not only this structure resembles a seahorse, but already 
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around 300 BC - 300 AD, members of the Alexandrian School of Medicine noted its 
similarity to the coiled horns of a ram (Figure 11. Upper left) and named it Cornu 
Ammonis, which means Ammon’s horn, the horn of a ram shaped Egyptian god 
(Andersen et al., 2007). However, this term endured in the literature as describing the 
hippocampus circuitry areas Cornu Ammonis (CA) 1, 2 and 3, since they too resemble 
the horns of a ram (Figure 11. Right). 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Origin of hippocampus nomenclature from shape similarity.  
Left: Representation of the hippocampus formation in the human brain (adapted from Servier 
Medical Art, Powerpoint Image Bank). Center: Structure of human hippocampus dissected free 
(top) compared to a specimen of Hippocampus leria, common name seahorse (bottom) 
(preparation by László Seress in 1980). Right: Mouse hippocampus circuitry organization 
(evidenced by Nissl-stained coronal slices of mouse brain) (adapted from DeFelipe, 2011) (top) 
compared with the horns of the ram shaped ancient Egypt god Ammon (bottom). (Adapted 
photography from the Karnak Temple, Luxor, Egypt). Images are not in scale.  
 
Defining which cytoarchitectonically distinct brain regions comprise the hippocampus 
is a matter of debate. Consensually, the hippocampal formation is seen as group of 
distinct but related brain regions that act together as one functional system. These 
regions include the entorhinal cortex (EC), dentate gyrus (DG), hippocampus proper, 
subiculum, presubiculum and parasubiculum. These regions are linked, one to the next, 
by a large unidirectional neuronal pathway (Amaral and Witter, 1989). Often, as in this 
thesis, the word hippocampus is used to refer to the structure comprising the 
hippocampus proper and DG.  The hippocampus proper can be further divided in the 
Cornu Ammonis areas: CA1, CA2 and CA3 area (Lorente de Nó, 1934). Functionally, 
the hippocampus is a microcircuit, designated trisynaptic circuit (Andersen et al. 1971), 
with three main connections: EC → DG; DG → CA3; CA3 → CA1 (see Figure 12). The 
trisynaptic circuit is a unidirectional excitatory feedforward glutamatergic circuit. CA1 
45 
 
pyramidal cells provide the final output of this circuit and are highly regulated by the 
activity of inhibitory neurons, interneurons, before the final output is send. 
 
  
 
 
 
 
 
 
 
 
Figure 12. An illustration of the rodent hippocampal circuitry. The traditional 
excitatory trisynaptic pathway (entorhinal cortex (EC)–dentate gyrus–CA3–CA1–EC) is 
depicted by solid arrows. The axons of layer II neurons in the entorhinal cortex (EC) 
project to the dentate gyrus (DG) (red) through the perforant pathway (PP), including the 
lateral perforant pathway (LPP) (purple fibers) and medial perforant pathway (MPP) 
(green fibers). The dentate gyrus sends projections to the pyramidal cells in CA3 through 
mossy fibers (red). In CA3 are (blue), pyramidal cells also receive direct projections from 
EC layer II neurons through the Perforant Path. CA3 pyramidal neurons relay the 
information to CA1 pyramidal neurons through Schaffer collaterals (blue).CA1 receives 
also receives direct input from EC layer III neurons through the Temporoammonic 
pathway (TA) (orange). CA1 pyramidal cells provide the final output of this circuit to back 
to the EC. The dentate granule cells also project to the mossy cells in the hilus and hilar 
interneurons, which send excitatory and inhibitory projections, respectively, back to the 
granule cells. Adapted from Deng et al., 2010. 
 
The function of hippocampus was highly debated in the 18th and 19th centuries, but 
is nowadays well stablished to be involved in memory acquisition, spatial learning and 
navigation is (Stark, 2007). In physiological conditions, the recurrent connections in CA3 
area work as an auto-associative network and have been proposed as essential for 
reconstructing already encoded patterns and retrieving previous experiences 
(Hasselmo et al. 1995; Nakazawa et al. 2002; Rolls, 2007), which is fundamental for its 
role in memory. It has also been observed that the CA3 region generates sharp waves 
and high-frequency oscillation EEG patterns implicated in memory consolidation 
(Buzsáki and Silva, 2012). However, the same properties that allow CA3 pyramidal cells 
to generate high-frequency oscillations implicated in memory consolidation, also make 
them prone to generate ictal-activity. These are two: intrinsic bursting properties and 
recurrent excitatory synaptic connections. 
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CA3 pyramidal cells have an intrinsic burst propensity, apparently based on a 
relatively high density of calcium channels in their proximal dendrites (Engel et al., 
2007). Membrane depolarization not only may trigger conventional sodium action 
potentials, but also may open these calcium channels. The calcium influx causes a 
more prolonged depolarization of the cell, driving additional action potentials in a “burst”. 
When these bursts occur, they provide a potent drive not only to CA1 targets, but also 
to neighboring CA3 pyramidal cells. This occurs due to the recurrent excitatory synaptic 
connections CA3 pyramidal cells establish with one another. A gradual recruitment of 
CA3 neuronal activity can thus lead to synchronized burst discharges. These can have 
a physiological role in stablishing rhythms but a minor imbalance in inhibition of CA3 
neurons can easily result in ictal-activity that is relayed to CA1 pyramidal cells.  
However, CA3 area shows reluctance to generate seizures and continues to 
generate only brief interictal activity during intense CA1 seizures (Schwartzkroin, 1993). 
This happens due to two main reasons: strong inhibitory circuitry in CA3 area and burst-
genesis mechanism also antagonizes its genesis. The generated burst is thought to 
occur due to calcium channels, as previously stated. However, these cells also present 
a very effective mechanism for turning off these bursts – the after-hyperpolarization 
generated by calcium-dependent potassium channels (as explained in section 1.2.). 
Thus, the very mechanism of burst generation – calcium influx – also involves a self-
limiting process (the calcium activated hyperpolarization). Simultaneously, the same 
mossy fiber input that activates CA3 cells also drives local interneurons very effectively 
so that CA3 cells are tonically inhibited by a variety of interneurons subtypes. 
 
1.4.2. CA1 pyramidal cells 
CA1 pyramidal cells, on the contrary, have a high susceptibility to generate seizure 
activity. But only in the presence of a synchronous synaptic ‘drive’ from CA3 neurons 
(Barbarosie and Avoli, 1997). 
Similarities between CA3 and CA1 pyramidal cells include its morphology, a 
triangular soma shape, by which they are named after, and other key structural features, 
as a single axon, a large apical dendrite, multiple basal dendrites and the presence of 
dendritic spines (Spruston, 2008). 
Differences between CA3 and CA1 pyramidal cells are more extensive. They include 
less population heterogeneity, non-bursting activity, little or absent recurrent excitatory 
connections and a lower level of inhibition by interneurons. These characteristics, non-
bursting activity and little or absent recurrent excitatory connections, might led us think 
that CA1 pyramidal cells would be less prone to experience spontaneous seizure 
activity. In fact, that holds true to ictal-activity generation, but once that information is 
received form CA3 neurons, CA1 pyramidal cells do not possess the same level of 
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protective mechanisms that prevent seizure activity in CA3 neurons (strong inhibitory 
activity and accentuated after-hyperpolarization current). 
Along with subiculum neurons, CA1 pyramidal cells constitute the output cells of the 
trisynaptic circuit. If seizure activity is generated in CA1 susceptible neurons, it will then 
be relayed to other structures, as the EC, initiating a seizure foci. Thus, the functional 
integrity of hippocampal output neurons represents a critical control point in temporal 
lobe epileptogenesis (Barbarosie and Avoli, 1997).  
 For this reason, studying how antiepileptic drugs affect CA1 pyramidal neurons 
activity has become a common method to understand its mechanisms of action. 
Nowadays, we take advantage of the fact that CA1 pyramidal cells have been 
extensively studied since the 19th century and its electrophysiological properties are 
well characterized (Henze and Buzsáki, 2001). Their firing pattern is commonly regular 
spiking, showcasing accommodation: frequency of action potentials fired is lower when 
the number of action potentials is increased. Typically, the resting membrane potential 
is around -70 mV, the firing threshold around -55 mV, AP amplitude around 100 mV 
and lasts around 1-2 ms, with interspike interval varying with number of action potentials 
fired.  
 
1.4.3. Interneurons 
The major basis for local circuit communication within the CA1 area lies in 
interneuronal circuitry. As explained in section 1.2., interneurons present a high 
heterogenous population of cells, in terms of anatomy, molecular and firing pattern. 
They are identified by releasing GABA at their synapses. However, that information is 
no accessible during the experiment, so location, size and firing pattern are usually used 
for identification. In CA1 molecular layer, interneurons have a low distribution (only 10% 
are interneurons, 90% are CA1 pyramidal cells). Usually they are smaller than CA1 
pyramidal cells and are characterized by high frequency activity (in the range of 80 Hz, 
while CA1 pyramidal cells reach 30 Hz, under physiological conditions). In CA1 region, 
interneurons perform a variety of operations (feed-back inhibition, feed-forward 
inhibition and disinhibition, see Figure 13) that are specific to determined interneuron 
populations. 
In conjunction with CA1 pyramidal neurons, these cell not only represent the 
functioning of excitatory and inhibitory synaptic transmission but also have their function 
altered in epilepsy. For these,  both CA1 pyramidal neurons and interneurons are of 
main interest to understand the role of a putative antiepileptic drug. 
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Figure 13. Hippocampal operations performed by distinct populations of CA1 
interneurons (A) Schematic representation of a coronal slice of the hippocampus highlighting 
the CA1 region.  (B) Simplistic representation of forms of feedback and feedforward operations 
performed by interneurons. TAP – Temporoammonic pathway; SC – Schaffer Collateral fibers; 
EC – Entorhinal Cortex. Adapted from Rombo, 2015. 
 
Acute hippocampal slices 
In this work, the hippocampus is a structure of great value to be studied due to the 
following reasons, some already mentioned: 
- Is implicated in epilepsy: hippocampal sclerosis (HS) is an hallmark of TLE; 
- It is well characterized - CA1 pyramidal neurons are the most studied neurons of the 
brain, which provide a rich reference background in which to integrate our results; 
- It has well-defined cytoarchitecture shared by rats and humans – the least 
heterogeneous neuronal population, the somata and dendrites of pyramidal cells are 
arranged into well-defined layers and the extrinsic and intrinsic inputs are 
segregated; 
- Its study has revealed general properties, usually applicable in other areas of the 
central nervous system; 
- Acute hippocampal slices are stable for long periods; maintain their structural 
integrity, unlike cultures or cell homogenates; allow the study of specific circuits and 
brain networks in isolation; the electrophysiological recordings are more stable than 
in vivo recording since heartbeat and respiration of the experimental animal are 
eliminated, allowing for long periods of cellular recording; direct visualization of the 
slice enables the localization, identification and easy access the cells studied and 
also allows for drug application, which is otherwise blocked by the blood brain barrier. 
 
The main disadvantage of using hippocampal slices is the necessary lack of 
neuronal activity connecting other brain structures that are no longer connected to 
the hippocampus. However, even though the external connections of this 
microcircuit are impaired, the internal connectivity remains intact. 
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2. AIMS   
A new adenosine derivative, MRS5474, was previously shown to be a functional 
agonist of A1R in overexpressing cells and presented antiepileptic properties in vivo in 
a model of Pharmaco-Resistant Epilepsy (6 Hz), without observable side-effects (being 
these the main obstacle to use adenosine as a pharmacological approach to treat 
Pharmaco-Resistant Epilepsy). 
The main goal of the project is to understand the mechanism of action and the 
neuronal target of MRS5474. In this work, the following hypothesis was tested: 
MRS5474 decreases excitatory synaptic transmission in CA1 pyramidal cells of 
the hippocampus through A1R activation. 
 
  
 
 
 
 
 
 
 
Figure 14. Schematic representation of the proposed hypothesis tested. 
 
Decreased excitatory transmission is a strategy for seizure suppression and it is 
the main function of adenosine as an endogenous anticonvulsivant. However, the 
lack of the typical A1R activation in the periphery (mainly in the heart), inferred from 
a behavioral toxicity test, argues for a more complex mechanism of action of 
MRS5474. If its mechanism of action provide a selective characteristic for the central 
nervous system, it may represent a new promising pharmacological platform for 
Pharmaco-Resistant Epilepsy therapeutics.  
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3. TECHNIQUES 
3.1. Electrophysiological recordings in acute hippocampal slices 
3.1.1. Acute Hippocampal Slice Preparation 
Brain tissue was shown to be kept alive and healthy outside the body in ex vivo 
mammalian brain slices, since their synaptic activity and excitability remained similar to 
that observed in vivo (McIlwain et al., 1951; Collingridge, 1967; Yamamoto and 
McIlwain, 1996). Following the pioneering work from McIlwain and colleagues, the brain 
slice preparation has become one of the most commonly used experimental 
preparations in Neuroscience, in particular in hippocampal research. Indeed it has been 
the biological support for much of our understanding of neuronal function at the cellular 
and synaptic level, since it presents several technical advantages for the investigation 
of the central nervous system (see Table 10). 
 
Table 10. Advantages and disadvantages of hippocampal slices in Neuroscience research 
Advantages 
 Shared anatomy and circuitry of hippocampus between rodents and humans 
 Viability                            
Stable for long periods (6-7 hours) 
 Structural integrity     
Maintains cytoarchitecture and synaptic circuits, unlike cultures or cell homogenates 
 Specific circuit analysis in isolation  
 Stability of electrophysiological recordings              
More stable than in vivo recording since heartbeat and respiration of the experimental animal are 
eliminated, allowing for long periods of cellular recording 
 Direct visualization                                                   
Enables localization, identification and easy access the cells studied, accessible for optical imaging or 
electrophysiological studies 
 Accurate control of the environment of the slice                                                                                                         
Drugs can be applied in known concentrations either to the entire slice or to selected regions, which is 
otherwise blocked by the blood brain barrier; drugs could also be removed from the tissue when desired 
Disadvantages 
 Isolated structure  
Absence of afferent input from other brain structures that are no longer connected to the hippocampus 
 Non-optimal maintenance of tissue  
Compared to in vivo, oxygenation and resources have limited availability 
 Acute insult to the tissue due to slicing 
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Obtainment of acute hippocampal slices requires 1. Hippocampus dissection and 
slicing and 2. Slice recovery.  
In order to preserve as much as possible the integral properties of the slice, 1. 
Hippocampus dissection and slicing should be performed in: 
- Reduced time – prolonged delays result in deterioration of the tissue and reduced  
quality of the slices.  
- Reduced temperature – decreases cell metabolism, delays tissue deterioration and  
helps maintain the consistency of the cerebral tissue; 
- Reduced excitotoxic environment – higher glucose concentrations (10 mM) than  
                                              reported in vivo (0.47 – 4.4 mM) are neuroprotective 
(Schurr et al., 1989; Schurr 1999; Cater et al., 2003). 
Once the slices have been obtained, it is necessary to provide an adequate environment 
in which they can recover from the stress induced by hippocampus manipulation and slicing. 
To do so, 2. Slice recovery should be performed in an activity inducer environment, 
including: 
- Increased temperature (35 °C) – promote cell metabolism functioning. 
 
3.1.2. Patch-clamp 
The development of Patch-clamp technique in the late 1970s and early 1980 has 
revolutionized neuroscience research. Its importance has render their inventors, Neher 
and Sakmann, the Nobel Prize in Physiology or Medicine in 1991 and its discovery made 
it possible to record the currents of single ion channel molecules for the first time, which 
improved our understanding of the involvement of channels in fundamental cell processes 
such as action potentials and neuronal activity.   
Until today, electrophysiology is one of the sounding pillars of neuroscience and patch-
clamp one of the most common used techniques. Described in a simple way, the patch-
clamp technique allows for insight of the electrical activity of the neuron (whether a patch 
of the membrane or single ion channels). It is achieved by placing an electrode in the 
membrane patch with such close proximity that they form a single electrical unit, where 
we can maintain (through clamping) the membrane potential to a desired value (Voltage 
hold, Vh, tipically -70 mV), in voltage-clamp mode. To do so, it is necessary to constantly 
measure the actual membrane potential and then apply the necessary electrical current 
to counter act it and maintain it at a fixed Vh. The necessary electrical current applied is 
monitored in a screen in live time and it is kept constant if the membrane potential of the 
cell is kept constant. Ideally, no current should be injected, which would mean that the 
neuron is already at the desired membrane potential. Whenever there is electrical activity 
in the neuron, its membrane potential will change and, consequently, the injected current 
will also change. In practice, we are indirectly measuring changes in voltage of the 
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membrane through injected current. This technique is based on Ohm’s law, that states 
that voltage (V) is equal to current (I) times resistance (R), equation 1. 
(eq. 1)        V =I x R 
Considering the resistance of the system to be maintained throughout the experiment, 
then changes in voltage are reflected by changes in current, and vice-versa. If the vice-
versa situation is considered, then we are in the presence of current-clamp mode. 
The key point that allowed this technique to work, apart from the electronic 
development, was the establishment of a tight proximity between the electrode and the 
membrane patch, such that they can work as a single electrical unit. That was made 
possible when Neher and colleagues (Neher, 1981) found out that very high resistance 
seals (in the order of 10-100 GΩ) can be formed between the cell membrane and the tip 
of a clean pipette when gentle suction is applied to the pipette interior. Along with the 
gigaohm seal technique, it was possible to gently pull the membrane patch with the 
attached pipette off the cell and study its trapped ion channels. Subsequently, it was found 
that the patch of membrane under the pipette tip could be removed, and once this had 
happened the electrode achieves direct electrical contact with the cell interior. As a result, 
the voltage across the entire cell membrane could be clamped, instead of the voltage 
across the tiny patch. This is how the technique came to be known as the whole-cell 
voltage-clamp.  
The voltage-clamp technique is often used to study one type of channels among the 
many present in a given cell. When this is the case, some procedures must be done to 
separate the currents through the channel of interest from the currents through any other 
channels. This can be achieved by selectively choosing the ionic composition of the 
pipette and/or the bath solution; by controlling the holding potential of the cell membrane; 
or by using different pharmacological agents that selectively block or activate specific 
channels or channel groups (see Sontheimer and Olsen, 2007 for review).  
Patch-clamp recordings can be performed in many different configurations that can 
involve the entire cell (whole-cell) or cell membrane excision and that may preserve 
(outside-out) or not (inside-out) the original exposure of the cell membrane to the 
extracellular medium. Recordings that maintain the cell structure can be performed in the 
cell-attached, whole-cell or in its variant, the perforated patch mode. Whereas the cell-
attached mode allows only for activity of the channels inside the pipette limit to be studied, 
the whole-cell and perforated patch modes allow the measurements of the currents 
flowing through the entire population of channels in a cell membrane (see Lien et al., 1995 
for review).  
Tipically, whole-cell mode is the most widely configuration used mode as it is easy to 
obtain and offers the possibility of applying modulators or drugs to the intracellular 
solutions in order to study signaling cascades associated to known phenomena.   
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4. METHODS 
All experiments were conducted in accordance with the Portuguese law on Animal Care 
and European Union guidelines (Directive 2010/63/EU). 
4.1. Animals 
Male young-adult wild-type Wistar rats (3-8 weeks old, Crl:WI, strain 003) were used in 
all experiments. The animals were housed in the local Animal House (Animal Biosafety 
Level 2) with standardized humidity, temperature and a 12 hours light/dark cycle in groups 
of 5-8 animals and were provided conventional food and water ad libitum. To be 
anesthetized, animals were transported from the Animal House in the same type of cages 
(covered with the same type of bedding as before) and had access only to water before 
being anesthetized. Care was taken so as to reduce animal suffering and the number of 
used animals to the absolutely necessary. 
 
4.2. Electrophysiology in acute hippocampal slices  
Measuring electrophysiological properties of hippocampal cells or circuits is a method 
that can be divided into three main steps (see Figure 15): 
1. Acute Hippocampal slice preparation (obtainment and recovery) 
2. Electrophysiological recordings (Patch-clamp whole cell) in hippocampal slice 
3. Data analysis 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Diagram of methodological approach – Electrophysiology in CA1 Pyramidal Cells 
in rat hippocampus. Wild-type male wistar rats (aged between 3-8 weeks) were used to 
obtainment of the brain (through euthanasia and decapitation). The hippocampus is dissected and 
cut into transversal 300 µm thick hippocampal slices, under appropriate conditions. After 
hippocampal slice recovery from slicing, electrophysiology recordings are performed under the 
method of patch-clamp whole-cell configuration. The recording electrode is placed in CA1 pyramidal 
cells, identified with a pink color. To study excitatory synaptic transmission, these cells are 
electrically stimulated either through the Schaffer Collateral fiber or the performant pathway with a 
 
8 
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stimulating electrode. Pharmacological isolation of the excitatory component of the synaptic 
transmission is achieved through perfusion of picrotoxin (50 µM), a GABAA ionotropic receptor 
blocker. Tested drugs are perfused into the system after stability of the electrophysiological 
recordings (CCPA 30 nM and MRS5474 120 nM). These can be divided into two groups: EPSPs 
recordings (inset) were obtained during experiments herein described and firing patterns, recorded 
to measure intrinsic excitability properties. 
 
The basic principle is to obtain a transversal hippocampal slice from the adult rodent 
brain ex vivo that remains viable for several hours(1), typically used to study the 
electrophysiological properties of individual neurons or circuits(2). 
 
1. Preparation of hippocampal slices for electrophysiological recordings 
Acute hippocampal cultures were prepared according to Rombo, 2015.  Briefly 
described, the animals were anaesthetized(a) (with Isoflurane, in 1,2-Propylenglycol 50% 
(v/v)) in an anesthesia chamber), sacrificed (by decapitation in an appropriate sized 
guillotine) and the brain quickly removed(b). The isolated brain was hemisected and the 
hippocampi dissected(c) and cut to obtain transverse(d) slices (300 µm thickness) on a 
Vibratome (Leica VT 1000S; Leica Microsystems, Germany), under an ice-cold(e) (4 ºC) 
oxygenated dissection solution containing (in mM): sucrose 110, KCl 2.5, CaCl2 0.5, MgCl2 
7, NaHCO3 25, NaH2PO4 1.25, glucose 7, pH 7.4, bubbled with 95% O2/5% CO2.  Once the 
hippocampal slices are obtained, they were first incubated for 20 minutes at 35ºC(f) in 
oxygenated artificial Cerebrospinal Fluid (aCSF) that contained (in mM): NaCl124, KCl 3, 
NaH2PO4 1.25, NaHCO3 26, MgSO4 1, CaCl2 2, glucose 10, pH 7.4 (gassed with 95% 
O2/5% CO2),   (Fredholm et al., 1984). After this period, slices are allowed to recover at 
room temperature (RT) (22-24⁰C) for at least 1 hour(g) before use in Patch-Clamp 
recordings.    
 
Notes: 
1- Quality of hippocampal slices is primordial to perform electrophysiological experiments  
(a) The first indications of anesthesia include the lack of a righting reflex and reduction in 
respiratory rate. A noxious stimulus (i.e. toe pinch) was also applied to ensure deep 
plane of anesthesia. If no response was noted, the animal was sacrificed by 
decapitation in a guillotine. Death by asphyxiation in the anesthesia chamber instead 
of anesthesia will compromise the quality of the hippocampal slices and it is not 
ethically acceptable. 
(b) It is very important to be as fast as possible in preparing the hippocampal slices. 
Prolonged delays result in deterioration of the tissue and reduced quality of the 
slices. A reasonable goal is to have cut slices separated in less than 5–10 min after 
the animal has been euthanized. 
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(c) Gentle and minimal manipulation of tissue is crucial to avoid damaging.  
(d) The transversal cut of hippocampal slices ensures that the entire trisynaptic circuit 
is obtained. If the slice is cut with a different angle, the circuit might not be complete 
and do not establish the correct connections between regions.  
(e) The low temperature of the cutting solution decreases the cell metabolism and helps 
maintain the consistency of the cerebral tissue. Keeping all dissection solutions cold 
and performing the entire procedure over ice helps delaying the deterioration of the 
tissue during dissection. 
(f) After hippocampal dissection and slice preparation, it is necessary to ensure the 
energetic and functional recovery of the tissue. 
(g) To maximum hippocampal slice quality, it is advisable to wait 3 hours before starting 
the electrophysiological experiment (Fiala et al., 2003). 
 
2. Electrophysiological recordings (Patch-clamp whole cell) in hippocampal slice 
Four main requirements are necessary to perform electrophysiological recordings in 
a setup: (1) environment: to keep the preparation healthy and administer drugs; (2) 
optics: to visualize the preparation; (3) mechanics: to stably position the microelectrode; 
and (4) electronics: to record and amplify the signal.  
 
1. Environment 
Individual dorsal hippocampal slices were placed in a submerged recording chamber 
(Luigs & Neumann, Ratingen, Germany) and continuously superfused by a gravitational 
superfusion system at 3-4mL/min with oxygenated aCSF at RT. Unless otherwise stated, 
drugs were added to this superfusion solution and reached the recording chamber within 
2-3 minutes.  
2. Optics 
CA1 pyramidal cells were visually identified using a Carl Zeiss Axioskop 2FS upright 
microscope (Jena, Germany) equipped with a 40x immersion objective with 2 and 4 zoom 
(i.e. up to 160x magnification) and a differential interference contrast-infrared (DIC-IR) 
CCD video camera (VX44, Till Photonics, Gräfelfing, Germany).  
3. Mechanics 
Physical stability is obtained through a vibration isolation table in the electrophysiology 
rig (Luigs & Neumann, Ratingen, Germany), controlled micromanipulators (Technical 
Manufacturing Corporation, Germany) and fixing the individual hippocampal slices with 
a harp slice grid with nylon strings (HSG-5BD, ALA Scientific Instruments, Farmingdale, 
NY, USA) to minimize agitation. 
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4. Electronics 
Whole-cell recordings were obtained from pyramidal cells located at CA1 stratum 
pyramidale of rat hippocampus.  
Recording Patch pipettes were made from borosilicate glass capillaries (1.5 mm outer 
diameter, 0.86 mm inner diameter, GC150F-10, Harvard Apparatus, Holliston, MA, USA) 
in two stages on a pipette puller (PC-10 Puller, Narishige Group, London, UK). The 
resistances of the recording pipettes were 4-9MΩ(a) when filled with an internal solution(b) 
containing (in mM): K-gluconate 145, HEPES 20, KOH 10, NaCl 8, KOH-EGTA 0.2, ATP-
Mg 2, GTPNa 0.3, pH 7.2 adjusted with KOH (1M), 290-300 mOsm. 
Whole-cell access was established following formation of a gigaseal (>1 GΩ) between 
pipette tip and cell membrane(b). Cells were voltage-clamped at Vh = -70 mV (with a EPC-
7 amplifier, List Biologic, Campbell, CA), digitized at 10kHz using a Digidata 1322A board 
and data acquired through Clampex software version 10.2 (Molecular devices, Sunnyvale, 
CA, USA). Offset potentials were nulled directly before giga-seal formation. Immediately 
after establishing whole-cell access, the membrane potential of the neurons was routinely 
determined at the beginning of each experiment as well as firing patterns, measured in 
current-clamp mode, to confirm CA1 pyramidal cell identity. Junction potentials and voltage 
errors caused by small changes in series resistance were not corrected, but series 
resistance was regularly monitored throughout each experiment with a -5mV, 50ms pulse, 
and cells with more than 20% variation over time were excluded from the data. Holding 
current was also monitored and recordings were rejected if the holding current was greater 
than − 100 pA or if it abruptly changed.  
 
Notes 
2- Quality of giga-seal is fundamental for quality and stability of electrophysiological 
recordings 
GigaOhm seal obtainment: Positive pressure avoids the tip of the pipette to acquire 
debris(c). When the tip of the pipette is in close contact with the cell membrane, a ‘dimple’ 
is seen: it results from the physical contact between the pipette and the membrane, which 
is optically visible with a lighter reflection. Simultaneously, the pipette resistance increases 
due the blockade of electrical flow by the cell membrane. To obtain the gigaohm seal, 
negative pressure is applied and a resistance superior of 1 GΩ is rapidly achieved. To 
enter in whole-cell configuration, a fast strong pulse of negative pressure is applied, 
allowing patched membrane rupture and direct contact between pipette and cell content(b). 
(a) Pipette resistance correlates inversely with tip opening diameter, which can not be to 
small (easy to seal, but difficult to obtain whole-cell configuration) nor to large (difficult 
to seal, but easy to rupture cell membrane). 
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(b) Internal solution is in direct contact with cell content in whole-cell configuration. Over 
time, the internal solution replaces the cell content (phenomenon known as “cell 
content dialysis” since the internal solution volume is greater than cell volume). It is 
crucial that the internal solution is electro-chemically similar to the cell content and 
allows for desired recordings. 
(c) Pipette tip ‘cleanliness’ is fundamental to assure a full seal between pipette tip and 
membrane, without cellular debris in between. 
 
Electrically-evoked excitatory postsynaptic currents (eEPSCs)  
Afferent-evoked excitatory postsynaptic currents (EPSCs) were elicited by 0.1 ms 
rectangular pulses (0.1 – 0.5 mA), delivered once every 15 s through a bipolar concentric 
wire electrode manually fabricated from platinum/iridium wire (25 µm diameter, <800 kΩ 
impedance (Advent Research Materials) positioned either in the Schaffer collaterals 
afferents or Perforant Pathway. EPSCs were recorded from pyramidal cells from CA1 area, 
voltage-clamped at Vh = -70 mV and perfused with aCSF containing picrotoxin (PTX, 
GABAAR antagonist, 50 µM) to block the fast component of GABAergic transmission. 
eEPSC recordings were started not before the first 5–10 minutes after break-in to enable 
diffusion of intracellular solution in the soma and proximal dendrites. After 10 minutes of 
eEPSC amplitude stability, tested drugs were applied in the perfusion system (CCPA 30 
nM, MRS5474 120 nM, DPCPX 100 nM). Averages of four consecutive individual 
recordings were used to plot and analyse data and the 10 minutes period before bath 
application of the drug was compared to the 30-40 minutes following its application.   
 
Firing patterns  
Firing patterns of CA1 pyramidal cells were determined in current-clamp mode 
immediately after achieving whole-cell configuration by a series of hyperpolarizing and 
depolarizing steps of current injection (1 second duration). Apart from visual identification 
through morphology (pyramidal shape) and location (somata in layer stratum pyramidal), 
CA1 pyramidal cells are characterized by slow firing frequencies (≤5Hz), longer action 
potentials (≥0,8ms) and for featuring spike-frequency adaptation (Figure 16). Increased 
depolarizing steps of current injection increased firing frequency until maximum firing 
frequency was reached. From that moment on, inactivation of voltage-dependent Na+ 
channels prevented the firing of more than a few initial action potentials. The analyzed 
population of CA1 pyramidal cells presented resting membrane potential of -62.0±5.8 mV 
(mean±SD) (n=93 cells), in accordance with the literature (-62.5±4.0 mV, Henze and 
Buzsáki). Characterization of the model used, pyramidal cells from CA1 area of acute 
hippocampal slices is in accordance with the literature, validating the used model.  
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Figure 16. Localization, morphology and physiological properties of CA1 pyramidal cells in 
acute rat hippocampal slices. (A) Acute rat hippocampal slices exhibit defined cytoarchitectonic 
organization, with distinct structures, divided into Dentate Gyrus (DG) and Cornu Ammonis (CA) 
areas, subdivided in CA1, CA2 and CA3 areas, which are also subdivided in defined strata (or 
layers) (B) Stratum pyramidale (CA1) contains the cell bodies of pyramidal cells, the principal 
excitatory neurons of the hippocampus, disposed in a strata easily identified by the naked eye. (C) 
Pyramidal cells (PC) are morphologically characterized by a triangular shaped cell body (arrow) 
with a single axon and multiple basal dendrites. (D) Pyramidal cells are also identified functionally 
by their firing patterns in response to current injection through the recording electrode, as described 
in Methods. Note accommodation of firing frequency (time interval between 2 last action potentials 
(APs) is longer when compared to 2 first APs). Images and recordings in this figure were obtained 
for the purpose of this work. 
 
Pharmacological tools  
Isoflurane was from Abbot Laboratories (Barcelona, Spain).  DPCPX (1,3-dipropyl-8-
cyclopentylxanthine) (selective antagonist of A1R), CCPA (selective agonist of A1R), 
Picrotoxin (GABAAR antagonist) and MRS5474 were from Tocris Bioscience (Bristol, UK) 
and were prepared as a 5 mM stock solution in dimethylsulfoxide (DMSO). The percentage 
of DMSO in each experiment did not exceed 0.01%. Stock solutions were aliquoted and 
stored at -20°C until use. Dilutions of these stock solutions to the final concentration were 
made freshly before each experiment.   
 
3. Data analysis  
Features from eEPSCs recordings and firing patterns were extracted with Clampfit 
(pClamp 9.2 software, Axon) off-line. Graphical plotting and statistical analysis were 
conducted with the Prism Version 6.0 for Windows (GraphPad Software).  
CA1 pyramidal cell images  
Images were obtained with QuickStarter Studio v.8 program and edited with ImageJ 
(version 1.42q; NIH, USA). 
eEPSC recordings 
As previously explained, series resistance was monitored on-line and assessed off-line 
as a parameter of experience validity (if >20% of variation was observed, the experience 
was rejected). Amplitude of eEPSC, Holding current and Input Resistance (referred to as 
Membrane Resistance in Results) were measured as detailed in Table 11 and described 
in Figure 17 as parameters of interest. Membrane potential variation due to applied drug 
St. Pyramidale (CA1) 
Electrode 
B PC C D 
200 pA 
15 ms 
25 mV 
CA1 
CA2 
DG 
A 
CA3 
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was estimated, based on Ohm’s Law (for more details, see Figure S2). In each experiment 
of eEPSC recording, averages of four consecutive individual recordings were used to plot 
time courses. Values refer to mean peak amplitude of eEPSCs and are represented as 
mean ± Standard Error of the Mean (SEM) from n experiments. Effect of tested drug was 
analyzed comparing baseline (10 minutes before drug application) with tested drug (30-40 
minutes after drug application). Statistical significance was assessed by a two-tailed 
Paired t test for the experimental versus control condition. A p value of 0.05 or less was 
considered to account for significant differences. 
 
Firing Patterns 
Firing patterns were elicited before each eEPSC recording as an additional mean of 
confirming CA1 pyramidal cell identity, as previously explained. A set of experiments were 
performed in which the goal was to obtain firing patterns as the final readout. To analyze 
the influence of the tested drug (MRS5474 120 nM) on intrinsic excitability parameters, 
resting membrane potential (RMP) and AP threshold were first analyzed and its difference 
calculated (ΔVm). This set of experiments arose from the increased excitability observed 
in eEPSC recordings, in which  AP firing was observed in 7 of 13 cells, from which only 6 
cells maintained series resistance < 20% variation. Other parameters were also analyzed, 
namely AP Amplitude, AP rising time, AP decay time, fAHP, mAHP, sAHP, firing 
frequency, accommodation index and rheobase. In Table 11 and Figure 17 a description 
of how the measurement was performed. All these parameters have in their biological 
basis ionic channels and they constitute a target of for neuronal excitability, since a small 
alteration in these channels/parameters has implications in microcircuit communication.  
 
RMP and AP Threshold: Cells with RMP > -50 mV were rejected. Outliers were 
identified as being >2x Standard Deviation of the population for that parameter. Cells that 
were identified as outliers in one parameter were usually also outliers for other parameters 
and, regardless of that, were excluded from data set for all parameters.  A pool of cells 
with maximal effect of MRS5474 (120 nM) at 1-2.5 hours after drug exposure was selected 
to analyze the effect of this drug in other parameters. To ensure the comparison between 
test treatment and control cells is valid, control cells were pooled so as the exposure to 
Picrotoxin and recovery period are within the same interval between control and test cells. 
Two tailed Unpaired t-test with Welch’s Correction was used to statistically analyze 
differences, except for the paired design experiment, where two-tailed Paired t-test was 
used. 
Firing Frequency:  one-way ANOVA followed by Bonferroni’s Multiple Comparison 
test was used. 
sAHP: as the amplitude of the slow afterhyperpolarization following a train of action 
potentials correlated with the number of action potentials, firing patterns were pooled that  
 responded with a spiking frequency of 16–20 Hz to a depolarizing current injection lasting 
1 s. 
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Table 11. Parameter Analysis  
Feature Measure  Relevance 
A. eEPSC Recordings  
Holding Current (pA)a Mean of Holding current (first 150 ms) 
Correlates with Membrane 
potential 
Amplitude (pA)b Difference between Peak Amplitude and Holding 
Current, after electrical stimulation 
Measure of level of synaptic 
transmission 
Input Resistance (MΩ)a Derived from mean amplitude current in response 
to the test pulses according to Ohm’s law (no 
capacitive currents flowing)  
Correlates with specific 
membrane resistance 
(Rinput=Rm/A). Reflects ion 
channels composition and 
functioning of the membrane 
Series Resistance 
(MΩ) 
Derived from peak amplitude current in response 
to the test pulses according to Ohm’s law  
Reflects the quality of the 
gigaseal. Parameter for 
experience validity 
Time of Peak (ms)b Difference between time of Peak Amplitude and 
time of Stimulus artifact 
Reflects ion channels 
recruited in synaptic 
transmission  
Membrane Potential 
(mV) 
Estimate based on Ohm’s Law: using holding 
current and membrane resistance, voltage is 
predicted 
Estimate to measure the 
effect of drugs in the level of 
cell excitability. 
   
B. Firing Pattern   
RMP (mV) Measured right after whole-cell break-in 
Intrinsic excitability 
properties 
 
AP Threshold (mV) Membrane potential at which its slope is >10 
mV/ms in first AP fired  
AP Amplitude (mV) Difference between AP Peak Amplitude and AP 
Threshold 
AP Rising time (ms) Interval of time between AP Threshold and AP 
Peak Amplitude 
AP Decaying time 
(ms) 
Interval of time between AP Peak Amplitude and 
relative minimum of fAHP 
fAHP (mV) Difference between first relative minimum after 
AP (typically 1-5 ms) and AP Threshold 
mAHP (mV) Difference between second relative minimum 
after AP (typically 20-100 ms) and AP Threshold 
sAHP (mV) Difference between AP Tail current negative 
going peak and mean membrane potential 
voltage (Vh) measured in the first 200 ms. 
Firing Frequency (Hz) Number of action potentials fired in a step of 
depolarizing current (interval of time is 1 sec) 
Accomodation index  Interspike interval of last two APs divided by 
interspike interval of first two APs. 
Rheobase (pA) Minimum Injected current necessary to evoke AP 
firing in an excitable cell. 
Notes: a – Mean holding current was measured avoiding miniature EPSC 
           b – If EPSC was polysynaptic, data refer to the first peak analyzed 
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Figure 17. Illustrated parameter analysis. A. Example of a typical trace of eEPSC recording 
obtained. B. Example of a typical trace of a firing pattern recorded in CA1 pyramidal cells. Analyzed 
parameters are indicated with red lines to graphically illustrate how analysis was performed. 
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5. RESULTS 
 
5.1. Activation of A1 adenosine receptors (CCPA 30 nM) inhibits excitatory 
post-synaptic transmission of CA1 pyramidal cells of rat hippocampus. 
Before testing the effect of MRS5474, it is important to test the consequences of A1R 
activation effect on excitatory synaptic transmission as a proof of concept control, despite 
its broad description in the literature. To do so, an A1R selective agonist was used, 
CCPA, at a concentration of 30 nM (100 fold superior to its Ki (0.4 nM). CCPA was 
applied in the bath of acute hippocampal slices of wt rat and CA1 pyramidal cell 
excitatory synaptic transmission recorded via patch-clamp (whole-cell) technique. CA1 
pyramidal cells were electrically stimulated at Perforant Path or Schaffer Colateral fibers 
that project onto CA1 pyramidal neurons. Since both are glutamatergic cells, excitatory-
excitatory synapses were studied (with GABAergic synaptic transmission blocked by 
picrotoxin (50 µM). 
 
5.1.1. CCPA (30 nM) decreases excitatory post-synaptic transmission 
CCPA (30 nM) application gradually inhibits EPSC amplitude upon 2-3 minutes after 
application, which is concordant with CCPA concentration in the perfusion bath. At 20 
minutes, maximum effect is reached and maintained. At 30-40 minutes, CCPA maximum 
effect was measured and it inhibited excitatory post-synaptic transmission by 70 ± 5.2 % 
(n=4, p=0.0009) (Figure 18). These observations are in accordance with the literature 
(inhibition of EPSC: 66 ± 3.0 % (n=8) Hargus et al, 2009). 
CCPA application did not seem to change the kinetic properties of the EPSC (Figure 
18.C.Inset) (assessed in monosynaptic signal, Figure S1) nor did it significantly change 
time of peak (12 ± 1.5 ms, n=4, p=0.1897) (Figure S1. E).  
At the end of each experience with CCPA (30 nM), selective antagonists of 
AMPA/Kainate (CNQX, 10 µM) and NMDA (DL-AP5, 50 µM) receptors should have been 
applied to confirm the EPSC was only due to glutamatergic synaptic transmission. 
However, it has been widely described in the literature that blockade of GABAAR by 
picrotoxin mainly inhibits GABAergic transmission and only glutamatergic synaptic 
transmission occurs (e.g. Jones and Kauer, 1999). 
 
5.1.2. CCPA (30 nM) hyperpolarizes membrane potential of post-synaptic CA1 
pyramidal cells of rat hippocampus 
Also in line with a decreased excitatory synaptic transmission, CCPA hyperpolarizes 
membrane potential, which reduces the probability of action potential firing by the cell. 
Hyperpolarization was directly measured by injected current and CCPA application was 
observed to cause a 29 ± 4,5 pA shift from original injected current (n=3, *p=0.0226) 
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(Figure 19). The time course of the changes in this parameter was very similar to the time 
course of amplitude change, reinforcing the idea that it is an effect of CCPA application. It 
is, however, more relevant to know, in mV, the degree of this hyperpolarization. It 
represents a hyperpolarization of 6.6 ± 0.55 mV (n=3, p=0.0075) (Figure 20.), in 
accordance with calculations using a model for membrane potential prediction based on 
Ohm’s Law, which was then validated (Figure S2). 
From the entire set of experiences of CCPA application (n=4), one was performed with 
a complemented intracellular solution that contained QX-314 (5 mM), a voltage-dependent 
sodium channel blocker that prevented the firing of action potentials. This experience was 
relevant in the context of the following experiences with MRS5474, therefore it will be 
analyzed further on. The important feature that matters to retain is that QX-314 (5 mM) 
presence did not impair CCPA effect on EPSC amplitude, even though it significantly 
changed injected current and membrane resistance from whole-cell onset independently 
form CCPA application in the perfusion system. For that reason, we did not include these 
results in hyperpolarization or membrane resistance analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Activation of A1 adenosine receptors (by CCPA 30 nM) inhibits excitatory post-
synaptic transmission of CA1 pyramidal cells of rat hippocampus. (A) Normalized averaged 
time-course changes in EPSC peak amplitude caused by superfusion of the selective A1R agonist 
CCPA (30 nM) (applied as indicated by the horizontal bar). Each point represents the average of 4 
individual responses, elicited once every 15 seconds. Data is presented as mean±SEM. (C) 
Representative EPSC averaged traces from one cell in (1) baseline (10 minutes before drug 
application) and (2) after CCPA application (30-40 minutes after drug application). Inset: Normalized 
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EPSC averaged traces.  (B) Averages of normalized EPSC peak amplitude of (1) baseline and (2) 
after CCPA application. (D) EPSC amplitude (pA) of all cells in (A), in baseline (1) and after CCPA 
application (2). Values from each cell are connected with line. Two tailed Paired t-test was used for 
statistical analysis of CCPA effect (**p-value < 0.01; ***p-value < 0.001).  n=4 cells, from 4 animals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Activation of A1 adenosine receptors (CCPA 30 nM) hyperpolarizes membrane 
potential of post-synaptic CA1 pyramidal cells of rat hippocampus. (A) Averaged time-course 
changes in Holding current (pA) - necessary to maintain whole-cell voltage-clamp recordings (Vh=-
70 mV) from CA1 pyramidal cells – caused by superfusion of the selective A1R agonist CCPA (30 
nM) (applied as indicated by the horizontal bar). Each point represents the average of 4 individual 
responses, measured every 15 seconds. Data is presented as mean±SEM. (C) Representative EPSC 
averaged traces from one cell in (1) baseline (10 minutes before drug application) and (2) after CCPA 
application (30-40 minutes after drug application).  (B) Averages of absolute change in Holding current 
of (1) baseline and (2) after CCPA application. (D) Holding current (pA) of all cells in (A), in baseline 
(1) and after CCPA application (2). Values from each cell are connected with line. Paired t-test was 
used for statistical analysis of CCPA effect (*p-value < 0.05).  n=3 cells, from 3 animals. All recorded 
cells had resting membrane potential more positive than -70 mV, around -66 mV. Upon CCPA 
application, it is necessary to inject less current to maintain the membrane potential at -70 mV. So, 
the membrane pontential hyperpolarized. 
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Figure 20. Predicted post-synaptic hyperpolarization effect of 
A1R activation by CCPA (30 nM). Physiologically relevant measure 
of CCPA (30 nM) hyperpolarization of membrane potential. Ohm’s 
Law is applied (ΔI corresponds to change in holding current; ΔR 
corresponds to total resistance approximation (Rm+Ra+Rp). Model 
validation in Figure S2. Values from each cell are connected with line. 
Paired t-test was used for statistical analysis of CCPA effect (**p-
value < 0.01).  n=3 cells, from 3 animals. Rm: Membrane Resistance; 
Ra: Series Resistance; Rp: Pipette Resistance. 
 
 
5.1.3. CCPA (30 nM) decreases Membrane Resistance  
CCPA (30 nM) application significantly decreased membrane resistance, by 9.9 ± 1.3%, 
(n=3, p=0.05) (Figure 21.). This has already been observed by others (Bannon et al, 2014) 
and results from K+ channel opening responsible for membrane potential 
hyperpolarization. According to Ohm’s Law, a decrease in membrane resistance would 
lead to an increased in the amplitude of EPSC. Since CCPA application inhibits the eEPSC 
amplitude, this inhibition can not be due to decreased resistance membrane. 
 
In this set of experiments, the effects observed in all experiences performed were 
reproducible, followed the same time course changes and presented relatively low 
dispersion of values, as assessed by Standard deviation. This is in accordance with a 
robust widely described effect of A1R activation. 
 
Confounding variables 
Confounding variables that may explain the decreased amplitude of EPSC in the 
presence of CCPA (30 nM) were studied, namely age, perfusion system rate, pipette 
resistance, slice thickness, pipette resistance, gigaseal and series resistance (Table 
S1). Even though no correlation analisys is possible to be performed due to the small 
amount of experiments (n=4), none parameter seemed to correlate with the EPSC 
amplitude, except perfusion system rate. Diminished perfusion system rate related with 
a smaller effect of CCPA on EPSC amplitude, which is expected if the time of analysis 
(30-40 minutes after CCPA application) is fixed.  
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Figure 21. Activation of A1 adenosine receptors (CCPA 30 nM) decreases membrane 
resistance of post-synaptic CA1 pyramidal cells of rat hippocampus. (A) Normalized averaged 
time-course changes in membrane resistance caused by superfusion of the selective A1R agonist 
CCPA (30 nM) (applied as indicated by the horizontal bar). Each point represents the average of 4 
individual responses, elicited once every 15 seconds. Data is presented as mean±SEM. 
(C)Representative averaged traces from quadratic pulse one cell in (1) baseline (10 minutes before 
drug application) and (2) after CCPA application (30-40 minutes after drug application). 
(B)Averages of normalized membrane resistance of (1) baseline and (2) after CCPA application. 
(D) Membrane Resistance (MΩ) of all cells in (A), in baseline (1) and after CCPA application (2). 
Values from each cell are connected with line. Two tailed Paired t-test was used for statistical 
analysis of CCPA effect (*p-value < 0.05).  n=3 cells, from 3 animals. 
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5.1.4. Inhibitory effect of CCPA (30 nM) on excitatory synaptic transmission is 
A1R-dependent 
To confirm that the inhibitory effect of CCPA in EPSC is an A1R mediated effect, we 
tested if the effect of CCPA (30 nM) is abolished in the presence of an adenosine A1R 
antagonist (DPCPX, 100 nM). The presence of DPCPX (100 nM) reversed the inhibitory 
effect of CCPA (30 nM) and even blocked the inhibitory tonus of A1R, by increasing EPSC 
amplitude and even led to action potential firing (Figure 22.).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Inhibitory effect of CCPA (30 nM) on excitatory synaptic transmission is 
A1R-dependent. (A)  Averaged time-course changes in EPSC peak amplitude caused by 
superfusion of the selective A1R agonist CCPA (30 nM) and A1R antagonist DPCPX (100 nM) 
(applied as indicated by the horizontal bars). Each point represents the average of 4 individual 
responses, elicited once every 15 seconds and data is presented as mean±SEM. Representative 
averaged traces are shown in (C), with number 1 representing EPSC of baseline (10 minutes 
before drug application), number 2 representing EPSC after CCPA application (30-40 minutes 
after drug application), number 3 representing EPSC after DPCPX + CCPA application (60-70 
minutes) and number 4 an action potential fired. To compare the effect of CCPA, averages of 
EPSC peak amplitude of baseline (10 minutes before drug application) and after CCPA application 
(30-40 minutes after drug application) are plotted in (B and D). Each one relative to (A) and (B), 
respectively. n=1 cell. 
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The number of experiences is too low, only n=1, for which more experiences should 
have been performed. However, this set of experiments is a standard A1R activation 
control which has been described in the literature, by Wu et al (1994) in CA1 neurons and 
Hargus et al (2009) in subiculum pyramidal neurons, in the hippocampal slice model, for 
example.  
The isolated effect of DPCPX (100 nM) on eEPSC peak amplitude should have been 
tested as a control. However, there are considerable observations in the literature for A1R 
antagonism leading to increased synaptic transmission, either by increasing extracellular 
calcium concentration in the synaptic and pyramidal cell soma layer (CA1 of rat 
hippocampal slices) (Schubert, 1988) or increasing synaptic transmission in fEPSC 
(Diógenes et al., 2014). 
 
This chapter provided the necessary control for A1R activation outcomes, which are in 
accordance with the literature. Being so, not only a classical activation of A1R is herein 
described and validated but also the operator ability to perform this technique was 
demonstrated. 
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6. DISCUSSION AND FUTURE WORK 
 
Adenosine acts as an endogenous anticonvulsivant (During and Spencer, 1992) 
(Figure 35) that was shown to protect against pharmacoresistant epilepsy (Gouder et al, 
2013). However its systemic administration also triggers unacceptable side effects, mainly 
cardiovascular (Monopoli et al, 1994; Gouder et al, 2013), that prevent its use as an AED. 
A new adenosine derivative MRS5474 was shown to protect against elicited seizures 
in the pharmacoresistant epilepsy model 6Hz in vivo without observable behavioral toxicity 
(up to 30 mg/kg), unlike the classical selective A1R agonist CCPA (Tosh et al, 2012).  
In this work, we aimed at determining the synaptic target of MRS5474, which could help 
to shift the search for new AEDs towards a novel target. Since MRS5474 was designed 
and shown to present high A1R affinity and full agonism with moderate selectivity, we 
hypothesized that MRS5474 decreases excitatory synaptic transmission through A1R 
activation in CA1 pyramidal cells of the hippocampus.  
 
6.1. CCPA is a classical A1R agonist 
Before testing MRS5474 (120 nM), we studied A1R activation by CCPA (30 nM). CCPA 
inhibited excitatory synaptic transmission by decreasing EPSC amplitude and membrane 
potential hyperpolarization. This effect was reversed in the presence of an A1R antagonist 
(DPCPX, 100nM), even though the number of experiences was too low (n=1). These 
results are already extensively described in the literature (Bannon et al, 2014; 
Heidarianpour et al, 2006, Dunwiddie and Fredholm, 1989), and the main objective was to 
test if in our experimental conditions we could detect A1R induced inhibition action of an 
A1R agonist. 
A1R activation by CCPA explains both its anticonvulsivant properties as well as the 
behavioral toxicity observed in vivo in the pharmacoresistant model of epilepsy (6 Hz) 
(Tosh et al, 2012). Since A1R are also present in the heart, A1R activation leads to 
suppressed automaticity of cardiac pacemakers and inhibition of AV-nodal conduction, 
resulting in decreased heart rate and blood pressure (Schindler et al, 2005; Mustafa et al, 
2009). These effects, even though not directly measured in Tosh et al. work (2012), may 
explain the inability of mice to stay in the rotarod platform during 1 minute without falling 
more than 3 times at a CCPA dose of 0.84 mg/kg (when ED50 (CCPA)= 0.12 mg/kg). 
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Figure 35. Anticonvulsivant mechanisms of A1R activation. (A) Pre-synaptic A1R 
activation results in lower Ca2+ influx, preventing neurotransmitter vesicles to dock and 
release its content to the synaptic cleft in a synchronized way. This process is described 
in the literature to be mediated by inhibitory G-protein activation that inhibits adenylate 
cyclase activity. This results in a lower production of cAMP from ATP, necessary to activate 
protein kinase A. Upon activation, protein kinase A phosphoriles Ca2+ channels, allowing 
its entrance into the intracellular environment. Therefore, lower cAMP concentration 
diminishes, through protein kinase A, the amount of phosphorylated Ca2+ channels, 
diminishing the entrance of Ca2+ to the cell. Since Ca2+ is necessary for neurotransmitter 
vesicle docking in the pre-synaptic membrane and posterior exocytosis of neurotransmitter 
content, lower concentrations of Ca2+ lead to decreased synchrony of neurotransmitter 
release, which is reflected in a lower amplitude EPSC. (B) Post-synaptic A1R activation 
explains membrane potential hyperpolarization (Bannon et al, 2014), since A1R are 
coupled to inhibitory G-protein which directly activate inward-rectifier potassium (GIRK) 
channels (Marck and Herlitze, 2000). It leads to K+ efflux, increasing the difference 
between membrane potential. Thus, the membrane potential is hyperpolarized. At the 
same time, opening of K+ channels decreases membrane resistance, which has also been 
observed. Both decreased neurotransmitter release synchrony and membrane potential 
hyperpolarization lead to decreased excitatory synaptic transmission, which contributes to 
a lower probability of seizure generation onset and propagation. 
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7. CONCLUSION 
 
Being able to use the adenosinergic system as a powerful anticonvulsivant mechanism 
for pharmacoresistant epilepsy opens the way to a strategy of treatment that had 
unfortunately been closed due to its severe side effects. 
MRS5474 is a new hope, since it is a new adenosine derivative that protects against 
elicited seizures in the pharmacoresistant model of epilepsy 6 Hz in vivo without 
observable side effects, unlike the classical selective A1R agonist CCPA. 
Searching for its synaptic target and mechanism of action, we have shown that 
MRS5474 is not a classical A1R agonist, since it does not decrease excitatory synaptic 
transmission in CA1 pyramidal neurons of healthy rat hippocampus, as occurs with 
selective A1R activation with CCPA. In spite of being unexpected, since MRS5474 was 
shown to have high affinity to A1R in overexpressing cells, it opens the way for a different 
mechanism of action that may explain the apparent absence of classical A1R side effects 
upon in vivo administration. 
In fact, we have also shown that MRS5474 presents a pro-excitatory role in intrinsic 
excitability of CA1 pyramidal cells in healthy rats, when studying excitatory synaptic 
transmission. RMP depolarization, increased firing frequency and decreased amplitude of 
AHP currents (fAHP and mAHP) support an excitatory role of MRS5474, which, by itself, 
is not able to explain the anticonvulsivant properties of MRS5474. However, it points 
towards a selective and complex mechanism of action, that can only be fully understood 
with a wider knowledge of MRS5474 effect on other system components, including 
inhibitory synaptic transmission of interneurons and CA1 pyramidal cells in healthy and in 
epileptic tissue. 
If the increased intrinsic excitability caused by MRS5474 on CA1 pyramidal cells is also 
observed at a greater extent in interneurons, then the global net effect of MRS5474 would 
be inhibitory. This hypothesis could explain not only its anticonvulsivant properties but also 
the lack of observable side effects. Unveiling the synaptic target of MRS5474 and its 
mechanism of action is, thus, an interesting track to bypass the negative implications of 
using the adenosinergic system and take advantage of its powerful anticonvulsivant 
properties against pharmacoresistant epilepsy.  
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